

Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: Kevin Schulman		
2. Your Title: Professor of Medicine		
3. The Entity(ies) You are Representing: Myself		
4. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No x
5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed. None.		
6. Please attach your curriculum vitae to your completed disclosure form.		

Signature: _____ **Date:** 02/12/2018 _____

CURRICULUM VITAE

February 2, 2018

KEVIN ALAN SCHULMAN, MD, MBA

OFFICE ADDRESS

Duke Clinical Research Institute
PO Box 17969
Durham, NC 27715

TELEPHONE NUMBERS

[REDACTED]
[REDACTED]
[REDACTED]

E-MAIL ADDRESS

kevin.schulman@duke.edu

HOME ADDRESS

[REDACTED]
[REDACTED]

DATE OF BIRTH

[REDACTED]

PLACE OF BIRTH

[REDACTED]

MARITAL STATUS

Married: 1996, Brenda Stacey Berlin
Children: 1998, Jacob Berlin Schulman
2000, Eli Berlin Schulman
2002, Micah Solomon Berlin Schulman
2004, Rebecca Berlin Schulman

LICENSURE

Pennsylvania, June 1990-December 1992
District of Columbia, October 1992-September 1999
North Carolina, September 1999-present

SPECIALTY CERTIFICATION

1991-present Diplomate, American Board of Internal Medicine (Recertification 2001, 2011)

EDUCATION

1983	BA	Dartmouth College
1988	MD	New York University School of Medicine
1988	MBA	The Wharton School of the University of Pennsylvania (concentration in health care management)

POSTGRADUATE TRAINING

1988-1989	Internship in Internal Medicine, Department of Medicine, Hospital of the University of Pennsylvania (Chair: Larry Early, MD)
1989-1991	Residency in Internal Medicine, Department of Medicine, Hospital of the University of Pennsylvania (Chairs: Larry Early, MD, and John M. Eisenberg, MD)

CURRENT PROFESSIONAL POSITIONS AND APPOINTMENTS

2001-present	Professor of Medicine, Duke University School of Medicine
1999-present	Director, Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine
1999-present	Research Associate, Center for Health Services Research in Primary Care, Durham VA Medical Center
2000-present	Faculty Associate, Trent Center for Bioethics, Humanities and History of Medicine, Duke University
2007-present	Associate Director, Duke Clinical Research Institute, Duke University School of Medicine
2009-present	Founding Director, Masters of Management in Clinical informatics, Duke University.
2011-	National Guest Scholar. Stanford Clinical Excellence Research Center (CERC). Stanford University School of Medicine
2015-	Faculty Governance Committee, Duke Science and Society Initiative. Duke University.
2016-	Visiting Scholar, Harvard Business School, Boston, MA
2016-	Gregory Mario and Jeremy Mario Professor, Duke University

PREVIOUS PROFESSIONAL POSITIONS AND APPOINTMENTS

1989-1991	Assistant Instructor of Medicine, University of Pennsylvania School of Medicine
1991-1992	Instructor of Medicine, University of Pennsylvania School of Medicine
1991-1992	Senior Fellow, Leonard Davis Institute of Health Economics, University of Pennsylvania
1992-1993	Medical Director, Clinical Economics Research Unit, Department of Medicine, Georgetown University School of Medicine
1992-1997	Assistant Professor of Medicine, Georgetown University School of Medicine
1992-1999	Program Faculty, Graduate Public Policy Institute, Georgetown University
1992-1999	Fellowship Director, Division of General Internal Medicine, Department of Medicine, Georgetown University School of Medicine
1993-1999	Director, Clinical Economics Research Unit, Department of Medicine, Georgetown University School of Medicine
1997-1999	Associate Professor of Medicine, Georgetown University School of Medicine
1999-2001	Associate Professor of Medicine, Duke University School of Medicine
2000-2013	Director, Health Sector Management Program, The Fuqua School of Business, Duke University
2000-2013	Director, Center for the Study of Health Management, The Fuqua School of Business, Duke University
2000-2001	Adjunct Associate Professor of Business Administration, The Fuqua School of Business, Duke University
2000-2004	Director, MD/MBA Program, Duke University School of Medicine
2001	Associate Professor of Business Administration, The Fuqua School of Business, Duke University
2003-2006	Vice-Chairperson for Business Affairs, Department of Medicine, Duke University School of Medicine
2000-2008	Affiliated Faculty, Center for Clinical Health Policy Research, Duke University School of Medicine
2008-2010	Senior Fellow in Clinical Health Policy, Duke Center for Clinical Health Policy, Duke University
2001-2010	Professor of Business Administration, The Fuqua School of Business, Duke University
2007-2016	Executive Committee, Duke Global Health Institute, Duke University
2013	Visiting Professor in General Management, Harvard Business School, Boston, MA
2014-2016	Visiting Professor in General Management, Harvard Business School, Boston, MA
2010-2016	Gregory Mario and Jeremy Mario Professor of Business Administration, Duke University

AWARDS, HONORS, AND MEMBERSHIPS IN HONORARY SOCIETIES

1983	Graduation <i>cum laude</i> , Dartmouth College
1988	Graduation with distinction, The Wharton School of the University of Pennsylvania
1990	Henry Christian Award (for outstanding abstract in a subspecialty field), American Federation for Clinical Research (now the American Federation for Medical Research)
1990	Associates Member Prize for Outstanding Scientific Presentation, Society of General Internal Medicine
1990	First Prize, Lee B. Lusted Student Prize (for outstanding presentation by a trainee), Society for Medical Decision Making
1995-1997	Faculty Development Award in Pharmacoeconomics, Pharmaceutical Research and Manufacturers of America Foundation
1999	Alice S. Hersch Young Investigator Award, Association for Health Services Research (now AcademyHealth)

2001	Dr. Herbert W. Nickens Epidemiology Award (inaugural recipient), Association of Black Cardiologists
2006	Elected Member, American Society for Clinical Investigation (ASCI)
2014-2015	Excellence in Teaching Award, Duke MMCi Program. Durham, NC.
2017	50@50 Notable People, Papers, and Events from the University of Pennsylvania Leonard Davis Institute's First Half-Century Award, for 1999 New England Journal of Medicine Article

MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

1989-present	Society for Medical Decision Making
1995	Nominated for Trustee
1997-1999	Ideas Committee
1990-present	American College of Physicians
1990-1992	Associate
1992-2010	Member
2010-	Fellow
1990-present	American Federation for Medical Research
1990-present	Society for General Internal Medicine
1993-2001	Research Committee
1997-2001	Finance Committee
1997	Glaser Award Selection Committee
2001	Co-chair, Patient-Centered Abstracts Review Committee
2009-2011	Research Subcommittee of the Health Policy Committee
1991-present	AcademyHealth
1996	Annual Research Meeting Planning Committee
1997	Annual Research Meeting Planning Committee
2001	Annual Research Meeting Planning Committee
2010-2013	Nominations Committee
1999-present	International Society for Pharmacoeconomics and Outcomes Research
2003	Program Chair, 8th Annual Meeting
2005-2009	Awards Committee; Vice Chair 2009, Chair, 2010-2012
2010	Candidate for President
2010-	The Business School Alliance for Health Management (www.BAHM-Alliance.Org)
2010-	Founding President

UNIVERSITY SERVICE

1990-1991	Medical Board's Committee on Quality Assurance Data and Systems, Hospital of the University of Pennsylvania
1992-1993	Clinical Research Working Group, Department of Medicine, Georgetown University School of Medicine
1992-1994	Practice Operations Committee, Department of Medicine, Georgetown University School of Medicine
1992-1997	Billing Committee, Department of Medicine, Georgetown University School of Medicine
1993	Pharmaceutical Promotion and Costing Education Committee, Department of Medicine, Georgetown University School of Medicine
1993-1994	Patient Care Information System Committee, Department of Medicine, Georgetown University School of Medicine
1996-1997	Quality Improvement Committee, Department of Medicine, Georgetown University School of Medicine
1997	Cochair, Supply Chain Management Task Force, Georgetown University School of Medicine
1997	Ad hoc Committee on Public Health, Georgetown University School of Medicine
1997-1998	Director, Medicare Coordinated Care Demonstration Project, Georgetown University School of Medicine

1997-1998	Thursday Group (executive leadership forum), Georgetown University School of Medicine
1998-1999	Ad hoc Committee on Clinical Problem Solving and Decision Making, Georgetown University School of Medicine
1998-1999	Committee on Faculty, Georgetown University School of Medicine
2000-2002	CERTs Database Workgroup, Duke Clinical Research Institute, Duke University School of Medicine
2000-2002	CERTs Quality Workgroup, Duke Clinical Research Institute, Duke University School of Medicine
2000-2003	Leadership for Executives in the Health Professions, Continuing Medical Education, Duke University School of Medicine
2000	Education Committee for the Health Policy Certificate Program, Terry Sanford Institute of Public Policy, Duke University
2000	Department of Biostatistics and Bioinformatics Chair Search Committee, Duke University School of Medicine
2001-2004	Steering Committee, Center for Genome Ethics, Law and Policy, Institute for Genome Sciences and Policy, Duke University
2001-2005	Faculty Compensation Committee, Academic Council, Duke University
2002-2007	Advisory Board, Duke Clinical Research Institute, Duke University School of Medicine
2003-2005	Advisory Council, Kenan Institute for Ethics, Duke University
2003-2013	Staff and Faculty Fringe Benefits Committee, Duke University School of Medicine
2004-2010	Executive Committee, The Fuqua School of Business, Duke University
2004-2006	Director's Advisory Board, Institute for Genome Sciences and Policy, Duke University
2005	Panel Judge, Snyderman Research in Medical Education Award, Duke University School of Medicine
2005-present	Oversight Committee. Duke/Coulter Translational Research Partnership, Duke University
2005	Working Group on the Environment and Health Sciences, Duke University
2005-2006	Global Health Institute Steering Committee, Duke University
2006-2015	Global Health Institute Executive Committee, Duke University
2005-2006	Planning Committee, 75th Anniversary of the Duke University School of Medicine
2007-2008	Duke Translational Research Institute Pilot Project Advisory Committee, Duke Translational Medicine Institute, Duke University
2009-	Member. Duke Comprehensive Cancer Center, Cancer Prevention, Detection and Control Program. Duke University Medical Center. Durham, N.C.
2009-2013	Executive Committee. Duke Center for Health Informatics (D-CHI). Durham, North Carolina.
2015-	Member. Faculty Governance Committee for the Duke Initiative for Science and Society. Durham, North Carolina.
2015-	Member. Executive Committee. Duke Clinical and Translational Science Award. Durham, NC.
2017-	Member, Promotions and Tenure Committee, Department of Medicine, Duke University

MAJOR TEACHING AND CLINICAL RESPONSIBILITIES

1987-1993	"Introduction to Health Insurance Theory for Medical Students" (annual lecture), New York University School of Medicine
1990-1992	Lectures on clinical economics and clinical decision making for medical interns, University of Pennsylvania School of Medicine
1991-1992	Teaching Instructor, Medical Clinic, Hospital of the University of Pennsylvania
1991-1992	Clinical Practice, Hospital of the University of Pennsylvania
1991-1992	Supervision of MD/MBA student for independent research project
1992	Coinstructor, "Health Economics and Clinical Decision Making" (Epidemiology 550), Master's in Clinical Epidemiology Program core course, University of Pennsylvania
1992-1996	Instructor, "Health Services Research: Clinical Applications," Graduate Public Policy Institute, Georgetown University
1992-1999	Teaching Attending Physician, General Internal Medicine Clinic, Georgetown University Medical Center
1993	Guest Lecturer, Minority High School Program, New York University School of Medicine
1997-1999	Instructor, "Economic Evaluation of Medical Care," Graduate Public Policy Institute, Georgetown University
1999-present	Coinstructor, "Health Economics in Clinical Research" (CRP 244), Clinical Research Training Program, Duke University School of Medicine
1999-2012	Instructor, "Health Care Systems and Policy," The Fuqua School of Business, Duke University

2000	Instructor, "Pharmaceutical Management and Policy," The Fuqua School of Business, Duke University
2000-2003	Preceptor, PRIME Ambulatory Care Clinic, Durham VA Medical Center
2000-2004	Coinstructor, "Medical Practice and Health Systems" (course for second-year medical students), Duke University School of Medicine
2000-present	Coinstructor, "Comprehensive Introduction to Clinical Research" (course for medical residents), Duke University School of Medicine
2001-2003	Lecturer, "Biotech for Business," Department of Chemistry, Duke University
2001-2012	Instructor, "Biotechnology: Management of Drug Discovery," The Fuqua School of Business, Duke University
2005-present	Inpatient Attending Physician, Durham VA Medical Center
2005-2006	Instructor, Duke MBA-Weekend Executive Seminar Series, The Fuqua School of Business, Duke University
2007-	Faculty Leader; Health Policy Lecture Series. Department of Medicine. Duke University School of Medicine.
2008-2009	Faculty Leader, Health Policy and Health Economics. Second Year Medical Student Intercession Course., Duke University School of Medicine.
2008	Faculty Leader, Global Crisis: <i>Healthcare</i> , The New Duke Advanced Management Program (AMP), Duke Fuqua School of Business.
2009-2016	Instructor, Federal Drug Administration (FDA) Commissioner's Fellows, "Biotechnology: Management of Drug Discovery", Silver Spring, MD.
2010-2012	Instructor, "Clinical Informatics and Strategy," The Fuqua School of Business, Duke University
2014-	Instructor, "Clinical Informatics and Strategy," The Duke University School of Medicine, Duke University
2014-2016	Instructor. "Global Health Care Systems." Duke University Master's in Global Health, Durham, NC
2013-2016	Visiting Professor. "Innovating in Health Care" Harvard Business School, Harvard University. Boston, Massachusetts.
2014	Visiting Professor. "Innovating in Biomedical Technology" Harvard Business School, Harvard University. Boston, Massachusetts.
2014-2016	Visiting Professor. "Innovating in Healthcare Field Course" Harvard Business School, Harvard University. Boston, Massachusetts.

STUDY SECTIONS

1992-1993	Ad hoc National Scientific Review and Evaluation Group, National Cancer Institute
1993	Site Visitor, Cancer Center Renewal Application, National Cancer Institute
1993	Panel Member, Special Emphasis Panel for Demonstration and Education Research Grants, National Heart, Lung, and Blood Institute
March 1994	Ad hoc Member, Clinical Trials Review Committee, National Heart, Lung, and Blood Institute
October 1994	Consultant, Clinical Trials Review Committee, National Heart, Lung, and Blood Institute
1994-	Ad hoc Reviewer, Agency for Healthcare Research and Quality (formerly the Agency for Health Care Policy and Research)
1996	Special Emphasis Panel Member, "Referrals from Primary to Specialty Care," Agency for Health Care Policy and Research
1996-1999	Ad hoc Reviewer, Clinical Trials Review Committee, National Heart, Lung, and Blood Institute
1997-2001	Cooperative Studies Evaluation Committee, Veterans Health Administration Cooperative Studies Program
1999, 2001	Reviewer, HCFO/Round 2 Health Tracking Proposal Review Meeting, Alpha Center and Robert Wood Johnson Foundation
1999-2006	National Advisory Committee, Investigator Awards in Health Policy Research, Robert Wood Johnson Foundation
2001	Review Panelist, "Studies of Adverse Effects of Marketed Drugs," Food and Drug Administration, Rockville, MD
2002	Reviewer, Special Emphasis Panel, Loan Repayment Applications, US Department of Health and Human Services
2002	Reviewer, Comprehensive International Program of Research on AIDS, National Institute of Allergy and Infectious Disease
2004	Reviewer, Ethical, Legal, and Social Implications of Human Genetics, Center for Scientific Review, National Institutes of Health

2004-2005	Reviewer, Coronary Revascularization in Diabetic Patients with Multivessel Disease Trial, National Heart, Lung and Blood Institute
2008	Reviewer, Centre for Health Economics, Services, Policy, and Ethics in Cancer Control (HESPE), National Cancer Institute of Canada
2009	Reviewer, NIH ELSI Centers of Excellence Review, Bethesda, Maryland
2008-	Reviewer, Susan G. Komen for the Cure/ASCO Cancer Foundation Research Initiative
2011	Reviewer, Disparities, Cancer Risk, Prevention & Prognostic Factors SEP Review, National Cancer Institute

MAJOR COMMITTEES AND APPOINTMENTS

1992-1995	Steering Committee, “Ethical Considerations in the Business Aspects of Health Care,” Seminar in Business Ethics, Woodstock Theological Center, Georgetown University, Washington, DC
June 1993	Faculty Member, Canadian Collaborative Workshop on Pharmacoeconomics, Health and Welfare Canada, Ottawa, Ontario, Canada
1994	Co-chair, National Cancer Institute Economic Conference--Integration of Economic Outcome Measures Into NCI-Sponsored Therapeutic Trials, National Cancer Institute, Bethesda, Md
1995-2004	Member, Clinical Economic Working Group, Cancer and Leukemia Group B (CALGB), National Cancer Institute, Bethesda, MD
1995-2003	Conference Grant Principal Investigator, Planning Committee (Chair, Abstract Review Committee, 1995; Cochair, Abstract Review Committee, 1997), National Research Service Award Trainees Research Conference, Agency for Healthcare Research and Quality and Health Resources and Services Administration
1996-1997	Chair, National Cancer Institute-American Society of Clinical Oncology Economics Workshop, Washington, DC
1998-1999	Total Artificial Heart Review Panel, National Heart, Lung, and Blood Institute, Bethesda, MD
2007-2012	Member, Roundtable on Translating Genomic-Based Research for Health, Institute of Medicine of the National Academies, Board on Health Sciences Policy, Washington, DC
2009	Member. Governor’s HIT Task Force Committee. State of North Carolina, Raleigh, North Carolina.
2010-2013	Member. Medicare Evidence Development & Coverage Advisory Committee (MEDCAC). Centers for Medicare and Medicaid Services, Department of Health and Human Services.
2010	Provenge MEDCAC Review Committee, CMS, Baltimore, MD
2010-2012	Physician Advisory Board, Blue Cross Blue Shield, NC.
2010-	Health Care Policy and Management Advisory Committee. China-Europe International Business School (CEBIS). Shanghai, China.
2012-2015	Scientific Advisory Board. Nutrition Science Initiative. San Diego, CA
2013-2017	Member, Kaiser Permanente Institute for Health Policy External Advisory Board.
2016-2017	Member. Committee of Health Care Utilization and Adults with Disabilities. National Academy of Sciences. Washington, DC.
2017-	Member. Leonard David Institute Executive Advisory Board. The Wharton School. The University of Pennsylvania. Philadelphia, PA.
2017-	Member, Advisory Board. Department of Health Sector Management and Policy. School of Business Administration. The University of Miami. Coral Gables, FL.

PANELS/SELECTED TALKS

1993	Panelist, Behavioral Working Group (Health Care Utilization), Women’s Interagency HIV Study, National Institute of Allergy and Infectious Disease, Bethesda, Md
1994	Working Group Member, “Secondary Prevention Strategies of CHD: Applications of ATP II Guidelines,” Division of Heart and Vascular Disease, National Heart, Lung, and Blood Institute, Bethesda, Md
1994	Session Chair, Annual Meeting of the Society for Medical Decision Making, Cleveland, Ohio
1994	Cochair, Plenary Session on Pharmacoeconomics, 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Orlando, Fla

1995	Panelist, Workshop to Build a National Strategy for Prevention, Management and Research in Chronic Obstructive Pulmonary Disease, National Heart, Lung, and Blood Institute, Bethesda, Md
1995	Cochair, Disease Management Short Course, Annual Meeting of the Society for Medical Decision Making, Tempe, Ariz
1995	Cochair, Disease Management Workshop, Drug Information Association, New Orleans, La
1995-1996	Working Group Member, "The Management of Patients with End-Stage Heart Failure," Northwestern University Medical School and Duke University Medical School Symposium, Orlando (1995) and Palm Beach, Fla (1996)
1995-1996	Planning Committee, Oncology Managed Care Program, Lombardi Comprehensive Cancer Center and Clinical Economics Research Unit, Georgetown University Medical Center, Bethesda, Md, and Arlington, Va (sponsored by Xerox Corporation)
1996	Participant, Mobile Breast Care Center Meeting, Department of Defense Telemedicine Test Bed, Office on Women's Health of the US Public Health Service, and National Cancer Institute, Bethesda, Md
1996	Session Chairperson, Pharmacoeconomics Workshop, Drug Information Association, New Orleans, La
1996	Panelist, "A Framework for Research and Evaluation into the Effects of Managed Care on the Pharmaceutical Marketplace," Pharmaceutical Policy Project of the Center for Health Policy Research, George Washington University, and the Office of the Assistant Secretary for Planning and Evaluation, US Department of Health and Human Services, Arlington, VA
1997	Education Session Chair, Outcomes Measurement, Annual Meeting of the American Society of Clinical Oncology, Denver, Colo
1997-1998	Panelist, "Ethical Issues in Managed Health Care Systems," Woodstock Theological Center, Georgetown University, Washington, DC
1997-1998	Panelist, Ad Hoc Outcomes/Cost-Effectiveness Advisory Panel, United States Pharmacopeial Convention, Inc, Rockville, Md
1998	Panelist, "Barriers to Conducting Outcomes Research on Medical Imaging in the Past and How the Barriers Can be Overcome" and "Utilization of Diagnostic Tests: Assessing Appropriateness," Methodological Issues in Diagnostic Clinical Trials: Health Services and Outcomes Research in Radiology, Office on Women's Health, Public Health Service, and National Cancer Institute, and ACR Commission on Research and Technology Assessment, Bethesda, Md
1998	Panelist, "Cost Management in Advanced Heart Failure," Advanced Heart Failure Meeting, Charleston, SC
1998	Panel Member, "The Economics and Financing of End-of-Life Care," Project on Death in America Meeting, Open Society Institute, Washington, DC
October 1999	Course Coordinator, "Prospective Economic Evaluation of Clinical Trials: Methods and Analysis," Annual Meeting of the Society for Medical Decision Making, Reno, NV
November 1999	Session Chair, "Economic Assessment in Clinical Trials: Design and Analysis" Drug Information Association, Orlando, FL
April 2000	Participant, "Assuring Appropriate Use of Pharmaceuticals: Balancing Cost and Quality," Prescription Drug Coverage: Rising Expenditures, Appropriate Use and Program Strategies, Agency for Healthcare Research and Quality, Washington, DC
September 2000	Coordinator, "Economic Evaluations of Multicenter, Multinational Clinical Trials," Second European Conference on the Economics of Cancer, European Organization for Research and Treatment of Cancer, Brussels, Belgium
September 2000	Panelist, "Race, Health Care, and Ethics: Speaking Truth to Power," Congressional Black Caucus Health Braintrust, Washington, DC
October 2000	Course Coordinator, "Prospective Economic Evaluation of Clinical Trials: Methods and Analysis," Annual Meeting of the Society for Medical Decision Making, Cincinnati, Ohio
December 2000	Panelist, "The Power of Physician Payment: Designing Incentives in a New Era," Changes in Health Care Financing and Organization, The Robert Wood Johnson Foundation. Washington, DC
2000	Panelist, "Solutions for Racial and Ethnic Disparities in Health Care," Institute for Diversity in Health Management, Advancing Health in America, Washington, DC
April 2001	Program Chair, "Internet Health Information Programs: Overview and Market Opportunities," Drug Information Association and Duke Clinical Research Institute, Durham, NC
May 2001	Panelist, "Breakfast with the Experts," Sixth Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Va
May 2001	Cochair, "Patient Centered Abstracts" Program Committee, Annual Meeting of the Society of General Internal Medicine, San Diego, Calif
June 2001	Session Chair, "Genetics and the Biotechnology Revolution," Annual Meeting of the Academy for Health Services Research and Health Policy, Atlanta, Ga

2001	Panelist, "The Productivity Factor: The Most Critical Variable," International Society for Technology Assessment in Health Care, Philadelphia, Pa
2001	Specified Data Solicitation Review Panel, Changes Health Care Financing and Organization, The Robert Wood Johnson Foundation, Washington, DC
2001	Panelist, "Ethical, Legal and Societal Issues in Biotechnology: A Primer for Industry Leaders," Center for Genome Ethics, Law and Policy, Duke University, Durham, NC
April 2002	Panelist, "Racial/Ethnic Bias and Health: Scientific Evidence, Methods, and Research Implications," Office of Behavioral and Social Sciences Research, National Institutes of Health, Vienna, Va
May 2002	Issues Panel Chair, "How Does Genomics Change Portfolio Management?," Seventh Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Va
2002	Panelist, Expert Meeting on Assessing the Spillover Effects of Managed Care on Medicare Fee-for-Service Expenditures, US Department of Health and Human Services, Washington, DC
2002	Panelist, "Challenges Seniors Face in Getting the Right Drug Therapy," Idea Rich Environment Discussion, United Health Group
2002	Session Codirector, "Coverage and Reimbursement: The Relationship Between Technology Approval and Reimbursement in the US: Where Are We? Where Are We Going?" Duke Clinical Research Institute, McLean, VA.
January 2003	Moderator, "Navigating the Pharmaceutical and Biotechnology Coverage of Reimbursement Process," Health Strategies Consultancy LLC, Washington, DC
May 2003	Program and Plenary Session Chair, Eighth Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Va
October 2003	Moderator, "Leading the Revolution in Health Care," Coach K Conference on Leadership, Duke University, Durham, NC
2003-2012	Avedis Donabedian Outcomes Research Lifetime Achievement Award Committee (Chair, 2007-present), International Society for Pharmacoeconomics and Outcomes Research, Arlington, Va
May 2004	Nominations Committee, Annual Meeting of the Society for General Internal Medicine, Chicago, Ill
June 2004	Planning Committee, AcademyHealth Annual Research Meeting, San Diego, California
October 2004	Moderator, "Challenges to the Generation of Clinical Evidence in Medical Device Trials," Medicare Coverage/Master the Changing Landscape, Health Strategies Consultancy LLC, Washington, DC
November 2004	Panelist, "What The 2004 Election Means for Health Policy in 2005 and Beyond," UNC-Duke Health Policy Forum, University of North Carolina at Chapel Hill
November 2004	Panelist, "Promises and Pitfalls of Web Publishing for Health Services Research: An Expert Meeting," AcademyHealth and the Agency for Healthcare Research and Quality, Washington, DC
February 2004	Panelist, Non-ST Elevation Myocardial Infarction Session, Fourteenth Annual Cardiovascular Conference, Beaver Creek, CO
2004-2009	Program Committee, Accelerating Anticancer Agent Development and Validation Annual Workshop, Duke Comprehensive Cancer Center with National Cancer Institute, American Association for Cancer Research, American Society of Clinical Oncology, National Cancer Institute, and others, Bethesda, MD
2004-present	Advisory Board Member, The Health Industry Forum, Schneider Institute for Health Policy, Brandeis University
2004-2011	Member, Data and Safety Monitoring Board, "Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)," National Heart, Lung, and Blood Institute
May 2005	Panelist, "Global Health and Reducing Disparities: The Role of the University," North Carolina Regional Meeting, Institute of Medicine of the National Academies, Duke University, Durham, NC
June 2005	Panelist, Symposium on the Integrity of Reporting of Clinical Research Studies, Association of American Medical Colleges, Washington, DC
November 2005	Panelist, "Who Pays? Who Benefits? A Discussion of Distributional Issues in American Health Care," Duke University School of Law, Durham, NC
November 2005	Panelist, "Fee-for-Service Trends: Evidence-Based Medicine in Part B," Second Annual National Medicare Prescription Drug Congress, Washington, DC
December 2005	Panelist, Economic Impact of Health Care Regulations Town Hall Meeting, Action to Reduce Regulatory Burden, Office of the Assistant Secretary for Planning and Evaluation, US Department of Health and Human Services, Chicago, Ill
2005	Dissertation Defense Discussant for Peter Lindgren, "Modeling the Economics of Prevention," Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
2005	Participant, "Cardiac Disease and Its Impact on Society," <i>Health Affairs</i> Theme Issue Planning Meeting, Washington, DC

2005	Technical Advisory Panel, Vanderbilt Center for Better Health, Vanderbilt University, Nashville, Tenn
2006	Duke University Health System/City of Durham Crime Initiative Steering Committee, Duke University, Durham, NC
2006	Panelist, "Discuss How New Approaches Could Work with the Case Example (Zometa)," Understanding the Benefits and Risks of Pharmaceuticals, Forum on Drug Discovery, Development, and Transition, Institute of Medicine of the National Academies, Washington, DC
2006	Participant, "Reinventing Health Care Delivery in the 21st Century," Council on Health Care Economics and Policy, The Robert Wood Johnson Foundation, Princeton, NJ
2006	Panelist, "The Future of Emerging Markets in Cardiovascular Biotechnology Pharma, and Medical Devices: Where is the Money Coming From and Where Is It Going?," SIS 2006: Emerging Technologies Symposium, Science Innovation Synergy, Bellevue, Wash
2006-2007	Member, "Development of a Practice Guideline Regarding the Use and Dosing of Warfarin, Based on Testing of CYP450 2C9 and VKORC1," American College of Medical Genetics Foundation
June 23, 2008	Session Chair and Discussant. "Doctors, Patients, and the Racial Mortality Gap: What are the Causes? "Neighborhood Differences and Health Disparities, The 2 nd Biennial Conference of the American Society of Health Economists (ASHE), Durham, NC.
June 23, 2008	Session Chair. "Hospital Quality." The 2 nd Biennial Conference of the American Society of Health Economists, (ASHE), Durham, NC.
June 24, 2008	Panel Discussant. "Information and Quality when Motivation is Intrinsic: Evidence from Surgeon Report Society for Health Economics, The 2 nd Biennial Conference of the American Society of Health Economists.
2009	Member, Planning Committee. "Systems Evaluation of Genome-Based Health Care". Institute of Medicine. Washington, DC.
2009	Member, Roundtable. "Effectiveness Research Innovation Collaborative (ER-IC)". Institute of Medicine. Washington, DC.
2009	Chair. Clinical Effectiveness Research Innovation Collaborative Committee (CER-IC), Institute of Medicine, Washington, DC.
2009-2010	Member. Commission on Accreditation of Healthcare Management Education Standards Council. MBA Task Force. Arlington, Virginia.
Nov 12, 2009	Panel Discussant, "Law School Panel on Health Care", Duke Forum of Law and Change. Duke University Law School. Durham, NC.
Feb 22, 2010	Panel Discussant. "Impact of Healthcare Reforms on Biotech", CED's Biotech 2010 Conference, Raleigh, North Carolina.
April 17, 2010	Panel Discussant, "Panel discussion on "Health Care: Why it passed – or failed...again", Duke Arts & Academics. Durham, North Carolina.
Sept 22, 2010	Panel Discussant, "Cost Savings and Consumer Preference", 2010-11 Harkness Fellows' Orientation Seminar, Harkness Fellowship in Health Care Policy and Practice. The Commonwealth Fund. New York, New York.
Oct 12, 2011	Moderator, Panel Discussion: Providers & Payers: What are their consumer programs and their challenges? Duke University's Third Annual Medical Innovation & Strategies Conference: Consumer Healthcare & Wireless Technologies. Durham, North Carolina.
Oct 15, 2010	Panel Member: Impact of Health Policy on Patient Care and Nursing Education Duke University. School of Nursing, Board of Advisors Meeting, Durham, NC
Oct 20, 2011	Panel member: Resolved: ACOs – Nice Idea, Won't Work. A Symposium Debate, 2011 Connected Health Symposium Driving Quality Up and Costs Down: New Technologies for an Era of Accountability, Boston, MA
Oct 21, 2011	Panel Member: Closing Panel: A Special Symposium Discussion 2011 Connected Health Symposium Driving Quality Up and Costs Down: New Technologies for an Era of Accountability, Boston, MA
2011-	Advisory Board Member. China-Europe International Business School (CEIBS) Centre for Health Care Policy and Management. Shanghai, China.
Nov 7 & 8 2011	Panel Member: Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020. "IOM Drug Forum Clinical Trials Enterprise Workshop". Washington, DC
Dec 3- 4, 2013	Faculty Leader, "Innovation in Health Care 2013: A Management Education Agenda." Duke University Medical Center, Durham, North Carolina.
Sept 14, 2015	Moderator: Session III, Specialty Pharmaceuticals Marketplace: Is Price Inelasticity Sustainable? 2015 Princeton Conference Report. The Council on Health Care Economics and Policy at Brandeis University. Princeton, New Jersey.
	Health Policy Expert. NEJM 360.

Sept 29, 2017 Panelist. Unbundling and rebundling health benefits: Innovative rethinking of health care delivery and competition. American Enterprise Institute, Washington, DC.

October 6, 2017 Moderator. Innovation Education for Life Sciences: Degree Students, Executives, and Professionals. Global Educators Network for Health Care Innovation Education (GENiE) Conference, Boston, MA.

2018- International Advisory Board Member. International Clinical Economic Evaluation Experts Cooperation Committee. Beijing, China.

LECTURES BY INVITATION

September, 1987 “Introduction to Health Insurance Theory for Medical Residents,” New York University School of Medicine, New York, NY

October 17, 1989 “Assessing Physicians’ Estimates of the Probability of Coronary Artery Disease,” Annual Meeting of the Society for Medical Decision Making, Minneapolis, Minn

February, 1990 “The Cost-Effectiveness of the Pharmacologic Treatment of High Blood Cholesterol,” Mid-Atlantic Regional Meeting of the Society for General Internal Medicine, Philadelphia, Penn

May, 1990 “Cost-Effectiveness of Low-Dose Zidovudine Therapy for Asymptomatic Patients Infected with Human Immunodeficiency Virus,” National Meeting of the American Federation for Clinical Research, Washington, DC

November, 1990 “Societal Costs of Liver Transplantation: Implications for Program Management,” Annual Meeting of the Society for Medical Decision Making, Boston, Mass

April 6, 1991 “Cost-Effectiveness of Low-Dose Zidovudine Therapy for Asymptomatic Patients Infected with Human Immunodeficiency Virus,” International Seminar Series: The Management of HIV Infection: Economic Aspects of HIV Management, The Wellcome Foundation, Lausanne, Switzerland

May 9, 1991 “Cost-Effectiveness as a Tool: Application to the Therapy of Hypercholesterolemia,” Endocrine Grand Rounds, Hospital of the University of Pennsylvania, Philadelphia, Pa

July 2, 1991 “Technology Assessment: Clinical Economic Impact of HA-1A Monoclonal Antibody for Gram-Negative Sepsis,” Annual Meeting of the Association for Health Services Research, San Diego, Calif

October 9, 1991 “Evaluations of the Results of Health Economics Studies: Quality of Life, Quantification of Benefits and Quality Adjusted Life Years,” Seminar on Health Economics, Presentation to the Director General of the Division of Pharmaceutical Affairs, Portuguese Health Ministry, Cascais, Portugal

October 23, 1991 “Prospective Economic Assessment of Medical Technologies: Methodologic Issues in Medicare Funding of New Technologies,” Annual Meeting of the Society for Medical Decision Making, Rochester, NY

November 12, 1991 “Evaluation of Cancer Diagnostic Tests: Understanding the Implications of New Technologies,” Office of Device Evaluation, Food and Drug Administration, Rockville, Md

May 13, 1992 “Economic Assessment of Pharmaceuticals: Formulary Assessment,” Ralph D. Arnold Pharmaceutical Services Management Course, US Department of the Army, Denver, Colo

May 25, 1992 “Economic Evaluation of HA-1A Therapy,” Annual Meeting of the Society of Critical Care Medicine, San Antonio, Tex

June 1, 1992 “Cost-Effectiveness of Cholesterol-Lowering Drug Therapy,” Annual Meeting of the American Society of Hospital Pharmacists, Washington, DC

September 22, 1992 “Integrating Economic Evaluations Into Phase III Clinical Trials: The Multidisciplinary Team,” Annual Seminar of the Project Management Institute, Pittsburgh, Pa

September 23, 1992 “Valuing Costs and Benefits of Pharmaceuticals,” Roundtable on Cost-Effectiveness and Public Policy, Institute for Public Policy Studies, Vanderbilt University, Nashville, Tenn

October 18, 1992 “Comparing Methods to Project Cost-Effectiveness Ratios from Clinical Trials,” Health Policy: Values, Outcomes and Choices, Annual Meeting of the Society for Medical Decision Making, Portland, Ore

October 19, 1992 The CDC Lookback Programs for HIV Transmission, Public Transmission: Public Safety from a Negative Epidemiologic Study

March 12, 1993 “Application of Economic Analysis to Clinical Practice: The Case of HA-1A Therapy,” Second Regional Symposium of the Canadian Coordinating Office for Health Technology Assessment, Calgary, Alberta

March 23-24, 1993	"Cost-Effectiveness: Definitions and Overview of International Approach. Critique of Guidelines, Clinical Data, Surrogate Endpoints, Economic Assessment of Pharmaceuticals," Meeting of the Drug Information Association, Sydney, Australia
April 26, 1993	"Integrating Cost-Effectiveness Analysis into Pulmonary Rehabilitation Research," NIH Pulmonary Rehabilitation Workshop, National Institute of Child Health and Human Development and National Heart, Lung, and Blood Institute, Bethesda, Md
May 1, 1993	"Economic Evaluation of Clinical Trials," Annual Meeting of the Society for General Internal Medicine, Washington, DC
June 21-22, 1993	"An International Perspective on Guidelines Development: Approaches, Challenges, and Future Directions--USA," Canadian Collaborative Workshop on Pharmacoeconomics, Health and Welfare Canada, Sainte-Adele, Quebec
December 7, 1993	"Economic Evaluation of Clinical Practice," Annual Meeting of the American Academy of Dermatology, Washington, DC
April 21, 1994	"Overview of Clinical Economics--Case Discussion: Stage II and III Breast Cancer," National Cancer Institute Symposium on Integration of Economic Outcome Measures into NCI-Sponsored Therapeutic Trials, Bethesda, Md
April 27, 1994	"Development of the Interactive Computer Program in Clinical Economics," Microcomputer Users Group Workshop, Annual Meeting of the Society for General Internal Medicine, Washington, DC
May 9, 1994	"Economic Evaluation in Clinical Trials," Annual Meeting of the Society for Clinical Trials, Austin, Tex
July 19, 1994	"Development of Multi-Media Educational Material: A Case Study Workshop," Annual Meeting of the American Association of Colleges of Pharmacy, Albuquerque, NM
September 20, 1994	"Pharmacoeconomic Claims in Drug Advertising (Rx2-87)," Annual Conference and Exhibition of the Regulatory Affairs Professionals Society, Washington, DC
October 1, 1994	"Essentials of Economic Evaluation," Economic Working Group, Cochran Colloquium, Ontario
October 7, 1994	"Overview of Pharmacoeconomics," 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Orlando, Fla
November 1, 1994	"New Uses of Multimedia in Computer-Assisted Learning," Association of American Medical Colleges, Boston, Mass
November 2, 1994	"The Role of Economic Evaluation in the Assessment of Therapeutic Efficacy for New Compounds," Food and Drug Administration Staff College, Bethesda, Md
November 10, 1994	"Using Economic Analysis to Determine Endpoints for Clinical Trials," Drug Information Association Conference on Cost-Effectiveness Analysis-Measures and Methods in Clinical Trials, Orlando, Fla
March 14, 1995	"Analysis of Pharmacoeconomic Data," Drug Information Association Biostatistics Conference, Hilton Head, SC
April 3, 1995	"Designing Trials for Economic Evaluations," International Symposium on Issues of Standardization in Economic Evaluations of Pharmaceuticals, Center for Pharmaceutical Outcomes Research, Chapel Hill, NC
May 5, 1995	"Economic Assessment of Cancer Therapies," Annual Meeting of the Cancer and Leukemia Group B, Providence, RI
June 6, 1995	"A Health Services Approach to the Evaluation of Innovative Pharmaceuticals and Biotechnology Products," Annual Meeting of the Association for Health Services Research and the Foundation for Health Services Research, Chicago, Ill
June 29, 1995	"Prospective Economic Evaluation of Clinical Therapies," Grand Rounds, Roswell Park Cancer Center, Buffalo, NY
July 31, 1995	"Approaches for Technology Assessment in Telemedicine in the Department of Defense," Session Provocateur, Chestertown Roundtable, Symposium of the Department of Defense Telemedicine Testbed Program, Chestertown, Md
September 22, 1995	"Pharmacoeconomics and New Drug Evaluation," Annual Meeting of the American College of Clinical Pharmacology, Rockville, Md
October 10, 1995	"Designing Trials for Economic Evaluations," Grand Rounds, Fairfax Hospital, Fairfax, Va
October 14, 1995	"Introduction to Disease Management," Disease Management Short Course, Annual Meeting of the Society for Medical Decision Making, Tempe, Ariz
November 6-7 1995	"What Are the Issues and Problems in Defining Quality Oncology Care?," Session Moderator, Oncology Managed Care Program, Xerox Corporation and the Lombardi Comprehensive Cancer

	Center and the Clinical Economics Research Unit, Georgetown University Medical Center, Bethesda, Md
November 10, 1995	“Designing Trials for Economic Evaluations,” Methodologies in Healthcare Outcomes in Gastroenterology: A Workshop Symposium, University of Illinois at Chicago Medical Center and the Gastroenterology Research Group, Chicago, Ill
December 1-2, 1995	“Methodological and Statistical Issues of Quality of Life and Economic Evaluation in Cancer Clinical Trials,” Session Chairperson, EORTC Symposium, Brussels, Belgium
December 5, 1995	“The Rationale for Disease Management,” Drug Information Association Disease Management Workshop, New Orleans, La
February 27, 1996	“Clinical Economics,” Grand Rounds, Howard University Hospital, Washington, DC
March 21, 1996	“Disease Management: Dissecting the Gatekeeper Model,” Agency for Health Care Policy and Research, Rockville, Md
April 19, 1996	“Reforming the Food and Drug Administration: The Pharmaceutical Approval Process,” American Enterprise Institute for Public Policy Research, Washington, DC
May 7, 1996	“HMOs’ Purchase of Tertiary Care Services in Three Markets,” Oncology Managed Care Program, Xerox Corporation with the Lombardi Comprehensive Cancer Center and the Clinical Economics Research Unit, Georgetown University Medical Center, Arlington, Va
July 31, 1996	“Cost-Effectiveness Issues in Screening Programs,” Mobile Breast Care Center Meeting, Department of Defense Telemedicine Testbed, Office on Women’s Health, Public Health Service and the National Cancer Institute, Bethesda, Md
August 24, 1996	“Designing Trials for Economic Evaluations,” Methodologies in Outcomes Research for Gastroenterologists Workshop, University of Illinois at Chicago Medical Center and the Gastroenterology Research Group, Seattle, Wash
September 6, 1996	“Study of Bone Diseases: Economic Evaluation,” Third International Bone Disease Symposium of the International Federation of Societies on Skeletal Diseases, in conjunction with the International Society for Clinical Densitometry, Chantilly, Va
October 24, 1996	“PBM Roundtable,” Center for the Study of Drug Development, Tufts University, Boston, Mass
November 1, 1996	“Economic Evaluation of Cancer Therapies,” Grand Rounds, Memorial Sloan Kettering Cancer Center, New York, NY
November 14-15, 1996	“Design of Clinical Trials for Economic Evaluation” and “The Results of the FIRST Study Economic Evaluation,” Drug Information Association Workshop, New Orleans, La
November 20, 1996	“Policy Issues in Pharmaceutical Cost-Effectiveness Research,” Discussant, American Enterprise Institute for Public Policy Research, Washington, DC
March 9, 1997	“Marketing of Generic Drugs,” Annual Meeting of the Generic Pharmaceutical Industry Association, Miami, Fla
April 17-19, 1997	“ACE Inhibitors for CHF: Comparative Economic Data,” Economics and Cost Effectiveness in Evaluating the Value of Cardiovascular Therapies, Duke Clinical Research Institute, St. Petersburg, Fla
May 18-19, 1997	“Outcomes Measurement” Education Session Chair, and “Health Services Research” Discussant, Annual Meeting of the American Society of Clinical Oncology, Denver, Colo
May 26, 1997	“Data Collection in Prospective Economic Studies,” Annual Meeting of the International Society of Technology Assessment in Health Care, Barcelona, Spain
July 23, 1997	“Clinical Economics and Reimbursement for New Technologies,” Ministry of Health and Welfare, Tokyo, Japan
July 23, 1997	“Economic Evaluation in Clinical Trials,” Keio University, Tokyo, Japan
September 19, 1997	“Designing Trials for Economic Evaluation,” Speaker and Session Chair, Methodologies in Healthcare Outcomes in Gastroenterology, Philadelphia, Pa
September 30, 1997	“The Relationship Between CD4 Count, Viral Burden, and Quality of Life Over Time in HIV-1 Infected Patients,” 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario
November 6, 1997	“Introduction to Economic Assessment in Clinical Trials,” Drug Information Association Workshop, Hilton Head, SC
February 3, 1998	“Comparative Research on Cost Effectiveness of Alternative Disease Treatments,” New York Pharma Forum, Inc, New York, NY
July 2, 1998	Speaker, “The Effect of Pharmaceutical Benefits Managers: Is it Being Evaluated?,” Pharmaceutical Issues Seminar, Consumer Federation of America, Washington, DC

September 24, 1998	"Bayesian Analysis in Laypersons' Terms," Session Chair, Health Economics and Outcomes Research: Making Statistics and Analysis More Relevant to Decision Makers, Medtap International and the Agency for Health Care Policy and Research, Chantilly, Va
October 3, 1998	"What Outcomes Research Tells Us About Cost-Effectively Managing Cardiovascular Risk," Heart to Heart Symposium, United HealthCare. Orlando, Fla
October 25, 1998	"Prospective Economic Evaluation of Clinical Trials: Methods and Analysis," Course Coordinator, Annual Meeting of the Society for Medical Decision Making, Boston, Mass
October 26, 1998	"The Effect of Race and Gender on Referral for Cardiac Catheterization," Annual Meeting of the Society for Medical Decision Making, Boston, Mass
October 29, 1998	"The True Costs of Pharmaceutical Therapy: Adverse Drug Reactions and Their Effect on the Health Care System," Quality of Care, Meeting on the Needs of Diverse Populations. 13th Annual Symposium of the Center for Clinical Quality Evaluation, Arlington, Va
November 10, 1998	"Economic Evaluation of Clinical Trials: Talking Past Customers," Economic Assessment in Clinical Trials: Design and Analysis, Drug Information Association Workshop, New Orleans, La
December 9, 1998	"The Effect of Race and Gender on Physician Recommendation for Cardiac Catheterization," Grand Rounds, Mayo Clinic, Rochester, Minn
March 9, 1999	"Effect of Race and Gender on Physician Recommendation for Cardiac Catheterization," Annual Scientific Session of the American College of Cardiology, New Orleans, La
May 7, 1999	"Moral Hazard Revisited: Is Health Insurance an Appropriate Financing Mechanism for Pharmaceutical Products?," Keynote Speaker, Fifth Wintergreen Conference of the University of Maryland and the Center on Drugs and Public Policy, Wintergreen, Va
May 14, 1999	"Academic-PRO Collaborations," DC Campaign for Medicare Excellence, Washington, DC
May 19, 1998	"Race and Gender Disparities in Health Care," Special Guest, Congressional Black Caucus, Washington, DC
May 20, 1998	"The Effect of Race and Gender on Physician Recommendation for Cardiac Catheterization," Office of Civil Rights Managers Conference, Office of Civil Rights, US Department of Health and Human Services, Washington, DC
June 10, 1999	"Race and Gender Bias in Clinical Decision Making," Women's Health Seminar Series, Department of Health and Human Services, Washington, DC
October 14, 1999	"Race as a Factor in Medical Decision-Making," Race, Ethnicity, and Medical Care: Improving Access in a Diverse Society, The Henry J. Kaiser Family Foundation, and Washington, DC
October 22, 1999	"Moral Hazard Revisited: Is Health Insurance an Appropriate Financing Mechanism for Pharmaceutical Products?" Program on Health Outcomes Seminar Series, University of North Carolina at Chapel Hill
November 8, 1999	"Race as a Factor in Physician Decision-Making," Eliminating Racial and Ethnic Disparities: Identifying Challenges and Building Partnerships, Mount Sinai School of Medicine and the Greater New York City Hospital Association, New York, NY
November 15, 1999	"Introduction to Economic Assessment in Clinical Trails: Design and Analysis," Drug Information Association, Orlando, Fla
April 3-4, 2000	"Internet Health Information Programs: Overview and Market Opportunities," Program Chairperson, Drug Information Association, Durham, NC
June 18, 2000	"The New Millennium: "The Impact of Genetics on the Structure of the Health Sector," The Charlene Worcester Memorial Lecture, Baptist Health System. Birmingham, Ala
March 29, 2000	"Maximizing the Value of Phase III Clinical Trials": Balancing the interest of the public in evidenced based medicine with access to new therapies and the need for return on investment by industry, Reducing Costs of Phase III Clinical Trials, Duke Clinical Research Institute, Vienna, Va
December 1, 2001	"Eliminating Racial Disparities in Health Care", Racial Disparities in Health Care Outcomes: Sources, Science, and Solutions, Student National Medical Association Regional Conference. Duke University Medical Center, Durham, NC
June 11, 2001	"Genomics and the Biotechnology Revolution" 2001 Annual Meeting of the Academy for Health Services Research and Health Policy, Atlanta, Ga
July 20, 2001	"Race, Sex, and Clinical Decision Making," Seminar Series on Methods in Health Disparities Research, Health Services Research, University of North Carolina at Chapel Hill
January 22, 2002	"Eliminating Racial Disparities in Health Care," Martin Luther King, Jr, Day Celebration, Duke University Medical Center, Durham, NC
January 24, 2002	"The Future of the Health Care System," Triangle Healthcare Executive Forum, Durham, NC
September 24, 2002	"The Implications of Genomics for the Practice of Medicine," Baptist Montclair Annual Medical Staff Meeting, Birmingham, Ala

November 1, 2002	"Results of the <i>NEJM</i> Survey," Conflict of Interest Roundtable Meeting, Duke Clinical Research Institute, Tysons Corner, Va
July 17, 2002	"Interpreting Racial Disparities in Access to Health Care," Ethics, Humanism and Health Care Policy Seminar of the Minority Medical Education Program. Duke University, Durham, NC
February 28, 2003	"Eliminating Racial Disparities in Health Care," Minority Health Conference, University of North Carolina at Chapel Hill
May 5, 2003	"Reaction to Bhattachayra's Work an Preserving Incentives to Innovate;" Integrity & Accountability in Clinical Research , 2nd Annual Clinical Research Conference, National Patient Safety Foundation, Queenstown, Md
October 25, 2003	"Implications of Health Disparities", NC Health and Wellness Trust Fund Commission, Greensboro, NC
November 1, 2003	"Eliminating Racial Disparities in Health Care," Mending the Health Care Divide: Eliminating Disparities in Access for Minority and Low Income Communities, University of North Carolina School of Law, Chapel Hill, NC
November 6, 2003	"Access to and Availability of Health Care Systems", 2003 Faith Conference, North Carolina Public Health, Greensboro, NC
November 12, 2003	"Barriers to Healthcare in Durham County," Durham Health Summit 2003, Durham, NC
March 20, 2004	"Louis Diamond Lecture: Integrating Business Principles into Nephrology Practice," Renal Physicians 2004 Annual Meeting, Washington, DC
November 11, 2004	"Economics of Oncology Drug Development," Breast Spore Workshop, Duke Comprehensive Cancer Center, Chapel Hill, NC
November 13, 2004	"A National Look at Quality of Health Care," Advancing Care & Practice: A Performance Challenge, 2004 Emerging Issues Forum, North Carolina Medical Society, Pinehurst, NC
February 16, 2005	"Issues of Health Policy and Their Impact on Acute MI Care," The Fourteenth Annual Cardiovascular Conference, William Beaumont Hospital. Beaver Creek, Colo
February 24, 2005	"The Impact of Being Uninsured on Status," Meeting of the Task Force on Covering the Uninsured, North Carolina Institute of Medicine, Cary, NC
April 25, 2005	"Economics in Decision-Making in Healthcare: Making the Case for Patient-Centric Health Records and Information," 2005 Almaden Institute, Transforming Healthcare with Information, IBM Almaden Research Center, San Jose, Calif
May 16, 2005	"Can Society Afford State-of-the-Art Cancer Treatment?" ASCO Plenary Session, 2005 Annual Meeting, Orlando, Fla
September 20, 2005	"The Economics of ICDs," 9th Annual Scientific Meeting, Heart Failure Society of America, Boca Raton, Fla
October 17, 2005	"Opportunities for Collaboration With Other Duke Schools and Institutes," Strategic Planning Meeting, Cancer Prevention, Detection, and Control Program, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC
October 27, 2005	"Disparities as Marker of System Performance," 75th Anniversary Celebration Medical Alumni Weekend, Duke University School of Medicine, Durham, NC
November 1, 2005	"Consumer-Driven Health Care," Triad Association of Health Underwriters, Greensboro, NC
May 17, 2006	"Economics of Drug Development," Accelerating Anticancer Agent Development and Validation Workshop, Duke Comprehensive Cancer Center, Bethesda, Md
June 2, 2006	"Health Economics 101: Does Cancer Treatment Cost Too Much?," The Cost of Cancer Care in the 21st Century: Challenges and Solutions, 2006 Annual Meeting of the American Society for Clinical Oncology, Atlanta, Ga
July 19, 2006	"Pharmacogenomics and Cardiovascular Business Strategy," SIS 2006: Emerging Technologies Symposium, Science Innovation Synergy, Bellevue, Wash
November 29, 2006	"Post Marketing Drug Surveillance," NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Meeting, Washington, DC
December 7, 2006	"Incentives for Innovation: Cancer Therapies in a Personalized Medicine Paradigm," Developing a Health Services Research Agenda on Emerging Cellular, Molecular, and Genomic Technologies in Cancer Care, National Cancer Institute, Bethesda, Md
December 4, 2006	"Creating the Climate for Personalized Medicine," The Genetic Age: The Era of personalized Medicine, Northwestern University, Chicago, Ill
June 5, 2007	"Benefit in Oncology: What Are the Criteria?" Translating Research into Practice, 2007 Annual Meeting of the American Society for Clinical Oncology, Chicago, Ill
September 25, 2007	"Quality from an Organizational Perspective," Duke Clinical Research Institute, Research Conference, Duke University Medical Center, Durham, North Carolina

October 3, 2007	"Accelerating Adoption of Personal Health Records." University of North Carolina, School of Public Health, Chapel Hill, North Carolina
October 5, 2007	"Collaborations Among Academia, Pharma, Biotech, and Government," National Cancer Policy Forum Workshop on Improving the Quality of Cancer Clinical Trials, Institute of Medicine of the National Academies, Washington, DC
October 8, 2007	"Health Care Costs and Projections," Health Policy Lecture Series, Department of Medicine, Duke University Medical Center, Durham, North Carolina
December 4, 2007	"Innovation: Understanding Types of Innovation and Implications for Policy," Roundtable on Translating Genomic-Based Research, Health Board on Health Sciences Policy, Washington, DC
March 19, 2008	"The Costs of Cancer Care," Hematology/Oncology Grand Rounds, Duke University Medical Center, Durham, North Carolina
May 5, 2008	"Health Care Disparities," Health Policy Lecture Series, Department of Medicine, Duke University Medical Center, Durham, North Carolina
June 5, 2008	"Quality and Strategy," Duke Educational Workshop, 2008 Thomson 100 Top Hospitals Summit, Colorado Springs, Colorado.
November 17, 2008	"Drug Safety", Cardiology Grand Rounds, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
March 12, 2009	"The Macroeconomics of Health Care in the US", Radiology Grand Rounds, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
April 14, 2009	"Dollars and Sense: Factors Pushing Clinical Research Out of the US," American Federation for Medical Research, The Current Crisis in Clinical Research Conference. Washington, DC.
April 23, 2009	"Challenges in Achieving a RO1 in Health IT Based on the Health IT Provisions of the American Recovery and Reinvestment Act of 2009", Keynote Speaker, Delivering on the Value Proposition for Connectivity and Health, The Fuqua School of Business, Duke University, Durham, North Carolina.
May 26, 2009	"Health Reform in the US; Implications for Hospitals and Organizational Design", Graduate School of Management, St. Petersburg, Russia.
June 20, 2009	"Creating Value in the Healthcare System", Keynote Speaker. The 5 th Annual China Health Care Forum 2009, Value Creation in Health Care. China Europe International Business School, Pudong, Shanghai.
June 23, 2009	"Clinical Construction of Pharmacoeconomics, Effectiveness, and Outcome Evidence", 45 th Drug Information Association Meeting, San Diego, California.
September 14, 2009	"Is Healthcare Recession Proof." Federation of India Chambers of Commerce and Industry (FICCI), Delhi, India
October 8, 2009	"Health Care, Health Insurance, and the Future of the Health System", Humanities in Medicine Lecture Series. Duke University Medical Center. Durham, North Carolina
November 7, 2009	"Organization Innovation: The Future Shape of Academic Medicine", Society of Clinical Surgery Meeting, Durham, North Carolina.
November 17, 2009	"Organizational Innovation in Healthcare: Lessons from Emerging Markets", Harvard School of Business. Boston, Massachusetts.
December 1, 2009	"Health Care Economics & Health Care Disparities", Health Policy Lecture Series, Duke University Medical Center. Durham, North Carolina.
June 4, 2010	"The Economics of it All, What Do We Need to Know?" Pharmacogenetics and Hepatitis: C: Unraveling new Pieces of the Puzzle. Beth Israel Deaconess Medical Center and Duke Clinical Research Institute. McLean, Virginia.
June 23, 2010	"Economics of Oncology Drug Development", 2010 Accelerating Anticancer Agent Workshop. Sponsored by FDA, the Duke Comprehensive Cancer Center, the NCI, AACR and ASCO. Bethesda, Maryland.
August 24, 2010	"Rethinking the Boundaries. Health Reform in the United States: Implications for Hospitals and Organizational Design". West China Hospital, Sichuan University, Chendu, China.
October 20, 2010	"Healthcare Reform: The Impact on Healthcare in the USA." Duke Club of Wilmington, Wilmington, NC.
October 22, 2010	"Healthcare Reform: Statement of the problem and implications for innovation." Keynote Address. Leading in Turbulent Times: Evolving Relationships in the New Health Care Arena. Feagin Health Policy Leadership Weekend. Duke University. Durham, NC
October 28, 2010	"Collaboration of key stakeholders to provide complementary and integrated interventions including data collection and feedback: leveraging health IT transformation" Medication

	Adherence: What do we need to get people to take their medicines? Duke Clinical Research Institute, Tyson's Corner, VA.
Nov 4 & 5, 2010	Yale University School of Medicine Visiting Professor. Yale University, New Haven, CT
June 12, 2011	"Technology and the Impact on Health Care Delivery", Emerging Market, Emerging Innovation, CEIBS 7 th Annual China Health Care Forum 2011, China Europe International Business School, Shanghai, China
Nov 9, 2011	Moderator, Panel Discussion. "Nursing Home & Assisted Living" Duke MBA Health Care Conference, Fuqua School of Business, Durham, North Carolina.
Nov 10, 2011	Panel Member: Obesity -Cardiac Disease –Diabetes, Business Solutions for a Global Epidemic, Fuqua School of Business, Durham, NC
Nov 16, 2011	Panel Member: Transformative Change in the Delivery System, Clinician Leadership for Health Care Reform: Reforming Policies and Reforming Care. Engelberg Center for Health Care Reform at Brookings, Brookings Institution, Washington, DC.
December 13, 2011	"Changing Paradigm of Healthcare Industry – The Need for Transformation", Health System Integration Council Meeting, VHA Southeast, Inc., Tampa, Florida
February 7, 2012	"Healthcare Delivery: The Role of IT Modernization" Challenges To Improving Healthcare Delivery: The Role of IT Modernization, Verizon Regional Kick Off, Verizon Connected Healthcare Solutions, Reston, Virginia
February 21, 2012	"Engaging Employees in Wellness Using Wireless Technology", HIMSS12 Conference, Las Vegas, Nevada
March 9, 2012	"Rethinking Boundaries", Board of Trustees Meeting, VHA Southeast Inc. Tampa, Florida
October 5, 2012	Discussant. 21st Century Health Care Management Education: Confronting Challenges for Innovation with a Modern Curriculum, Harvard Business School, Boston, Massachusetts
Oct 17, 2012	Moderator, Health Care Reform Panel. NCBIO Annual Meeting, North Carolina Biotechnology Research Center, Triangle Park, NC
October 23, 2012	"How Innovation is Driving Changes in Patient Behavior", 2012 Verizon Healthcare Customer Advisory Board, Verizon Enterprise Solutions, Boston, Massachusetts
Nov 13, 2012	CHANGE OF PLANS: The State of Healthcare & The Election, Duke University
December 4, 2012	"Recommendations for Implementation: Coverage", Atrial Fibrillation Think Tank, Duke University Medical Center, Tysons Corner, Virginia
March 4, 2015	"The Cost of Healthcare", Leadership North Carolina, Class XXII, Health and Human Services Session. Greenville, NC
March 18, 2015	"Specialty Pharmaceuticals and Personalized Medicine: An Economic Perspective", Cone Health, Greensboro, NC.
May 14, 2015	"The Cost of Cancer Care", US Oncology Network Spring 2015 Annual Conference. Coronado, CA.
Sept 18, 2015	"Healthcare Innovation". CERC National Guest Scholar. Center for Advanced Study in the Behavioral Sciences. Sanford University. Palo Alto, California.
January 15, 2016	Keynote Speaker: "The Pivot: From Fee for Service to Population Health". Medical Staff Annual Retreat. University of Arizona. Tucson, Arizona.
Mar 16, 2016	Speaker. Navigating The Transition to Value – "The Pivot from FFS to Population-Based Health." Research Triangle Foundation. Raleigh, NC.
June 23-26, 2016	Invited Participant. Aspens Ideas Festival Spotlight Health. Aspen, Colorado.
July 6, 2016	Panelist. Commonwealth Fund Initiative on Digital Health. New York, NY.
July 19, 2016	Faculty Leader. "Balanced Scorecard." Healthcare Leadership Academy. Abuja, Nigeria.
August 16, 2016	"Healthcare Innovation". CERC National Guest Scholar. Palo Alto, California (webinar)
September 14-15, 2016	Invited Participant. Alexandria Summit-Healthcare Economics. New York, NY.
September 17, 2016	Plenary Speaker: "The Economics of Precision Medicine." American Association of Neuromuscular and Electordiagnostic Medicine (AANEM) Annual Meeting. New Orleans, LA.
October 26, 2016	Session Chair. Innovation Management and Entrepreneurship in Life Science Degree Programs. GENIE 1 st European Edition with EIT Health and IESE Business School. Barcelona, Spain.
Nov 17, 2016	Visiting Professor. "Specialty Pharmaceuticals." The Wharton School, The University of Pennsylvania. Philadelphia, PA.
Nov 18, 2016	Speaker. "The Pivot." American Society of Echocardiography. ASE Board of Directors Meeting. Raleigh, NC
Nov. 25, 2016	Faculty. "Balanced Scorecard." Healthcare Leadership Academy. Abuja, Nigeria (webinar)
Dec. 13, 2016	Speaker. "Specialty Pharmaceuticals." Committee on Access to Affordable Drug Therapies. National Academies of Science. Washington, DC.

April 5, 2017	Keynote Speaker. "The Pivot." NCAHQ Annual Education Conference, Durham, NC.
May 3, 2017	Faculty Seminar. "The Pivot." UT Southwestern School of Medicine, Dallas, Tx.
July 26, 2017	Grand Rounds. "The Pivot." Stanford University School of Medicine. Palo Alto, CA.
September 29, 2017	Unbundling and rebundling health benefits: Innovative rethinking of health care delivery and competition. AEI. Washington, DC.
February 9, 2018	Intersocietal Accreditation Commission (IAC) Board of Directors annual meeting, "Transition From Fee-for-Service to Value: The Impact on Health Care Delivery Systems and Quality Measurement. Fort Lauderdale, FL.

EDITORIAL POSITIONS

1993-2003	International Editorial Board, <i>Pharmacoeconomics</i>
1994-1996	Working Party Member, "Methodological Guidelines for Economic Evaluations," <i>British Medical Journal</i>
1995	Scientific Editor, "National Cancer Institute Conference: The Integration of Economic Outcome Measures Into NCI-Sponsored Therapeutic Trials," <i>Journal of the National Cancer Institute Monographs 19</i>
1997-present	Editorial Board, <i>American Heart Journal</i>
1997-2011	Scientific Advisory Board, <i>Value in Health</i>
1997-2006	Editorial Board, <i>Disease Management</i>
1998	Scientific Editor, <i>Journal of the National Cancer Institute Monographs 24</i>
2000-2008	Editorial Board, <i>Evidence-Based Gastroenterology</i>
2001-2010	Editorial Board, <i>American Journal of Medicine</i>
2003-2016	Editorial Board, <i>Cost Effectiveness and Resource Allocation</i>
2006-2007	Guest Editor (with Neal J. Meropol), JCO Reviews Series, "Perspectives on the Cost of Cancer Care," <i>Journal of Clinical Oncology</i>
1996-2013	Editorial Board, <i>Health Services Research</i>
2013-	Senior Associate Editor, <i>Health Services Research</i>
2017-	Senior Associate Editor, <i>Health Management, Policy and Innovation</i>

PEER-REVIEWED GRANT SUPPORT

ACTIVE

5UL1-TR001117-05 (Boulware)	09/26/13 – 04/30/18	1.20 calendar
NIH	\$5,056,715	

Duke CTSA (UL1)

To fulfill the new NCATS vision for the CTSA Consortium and accelerate scientific discoveries into improved outcomes for patients, academic health and science systems must invest, transform, and innovate to optimize their unique strengths. Our vision, aligned with that of NCATS, is to create a research environment at Duke that stimulates the translation of scientific discovery from bench to bedside by 1) linking discovery science to a creative engine that efficiently accelerates development of new technologies; and 2) integrating clinical trials, registries, and electronic health records in a learning health system where research and practice form a continuum.

1K12-HL138030-01 (Bosworth)	09/01/17 – 08/31/22	0.60 calendar
NIH	\$308,452	

Dissemination and Implementation Science in Cardiovascular Outcomes (DISCO)

The goal of this K12 application is to accelerate clinical applications of laboratory findings relevant to improved diagnosis and management into practice. We will train a cohort of 5 Dissemination and Implementation scholars to be the next generation of researchers to engage in T4 translation research using rigorous qualitative and quantitative methods to examine the adoption, uptake, acceptability, affordability, fidelity, and sustainability of proven-effective interventions using established implementation frameworks to impact heart, lung, and blood diseases and sleep disorders. The long-range goal of this program is thereby to help ensure an adequate supply of well-trained researchers who will be able to confront the clinical problems HLBS medicine through well-designed, skillfully conducted and multidisciplinary clinical research.

*effort due to start on 12/1/17

NON-ACTIVE

Source:	National Institute of Child Health and Human Development
Role:	Investigator
Title:	Cooperative Community-Based Prenatal Intervention Studies in Minority Populations (Siva Subramanian)
Date of Entire Project:	9/01/92-8/31/97
Total Costs:	\$197,576
Source and ID No.:	US Department of the Army, MD17-94-J-2411
Role:	Principal Investigator
Title:	Does Physician Description of Therapeutic Options Influence Breast Cancer Patient Treatment Choice?
Date of Entire Project:	7/01/94-9/30/96
Total Costs:	\$142,873
Source:	National Institutes of Health and Health Resources and Services Administration
Role:	Principal Investigator
Title:	Institutional National Research Service Award
Date of Project:	7/01/94-6/30/99
Total Costs:	\$957,702
Source and ID No.:	The Robert Wood Johnson Foundation, 24328
Role:	Co Investigator
Title:	Selective Contracting for Tertiary Care Services by Managed Care Organizations
Date of Entire Project:	7/1/94-6/1/97
Total Costs:	\$71,383
Source and ID No.:	US Department of the Army, DAMD17-94-J-4212
Role:	Investigator, Member of Executive Committee
Title:	Cost-Effectiveness of Alternative Treatments for Local Breast Cancer in the Elderly
Date of Entire Project:	8/01/94-8/30/97
Total Costs:	\$120,807
Source and ID No.:	Agency for Health Care Policy and Research, 5-R01-HS08395
Role:	Investigator, Member of Executive Committee
Title:	Care, Costs and Outcomes of Local Breast Cancer in Older Women
Date of Entire Project:	9/30/94-9/29/99
Total Costs:	\$251,423
Source and ID No.:	Agency for Health Care Policy and Research, 1 R01 HS07315-01
Role:	Principal Investigator
Title:	Race and Gender Differences in Clinical Decision-Making
Date of Entire Project:	03/01/95-02/28/99
Total Costs:	\$1,073,654
Source:	PhRMA Foundation
Role:	Principal Investigator
Title:	Faculty Development Award in Pharmacoeconomics
Date of Entire Project:	7/01/95-6/30/97
Total Costs:	\$80,000
Source:	Agency for Health Care Policy and Research and Health Resources and Services Administration
Role:	Principal Investigator
Title:	1996 Second Annual NRSA Trainees Research Conference
Date of Entire Project:	5/1/96-4/30/97
Total Costs:	\$75,000

Source:	National Library of Medicine
Role:	Investigator
Title:	Project Phoenix: Scrutinizing Telemedicine Test Bed
Date of Entire Project:	9/30/96-1/10/99
Total Costs:	\$542,998
Source:	Agency for Health Care Policy and Research and Health Resources and Services Administration
Role:	Principal Investigator
Title:	1997 Third Annual NRSA Conference
Date of Entire Project:	4/1/97-3/31/98
Total Costs:	\$100,000
Source:	Government of the District of Columbia
Role:	Principal Investigator
Title:	Medicare Demonstration Project
Date of Entire Project:	6/1/98-11/1/98
Total Costs:	\$418,900 (planning budget)
Source:	Health Resources and Services Administration
Role:	Principal Investigator
Title:	Institutional National Research Service Award
Date of Entire Project:	7/1/98 – 8/31/99
Total Costs:	\$994,373
Source:	Health Resources and Services Administration
Role:	Principal Investigator
Title:	Institutional National Research Service Award/Supplement Award
Date of Entire Project:	7/1/98 – 8/31/99
Total Costs:	\$827,693
Source:	Agency for Health Care Policy and Research
Role:	Principal Investigator
Title:	Institutional National Research Service Award
Date of Entire Project:	7/1/98 – 8/31/99
Total Costs:	\$850,182
Source:	Environmental Protection Agency
Role:	Principal Investigator
Title:	Economic/Cost Analysis Associated with the Transition to CFC-Free MDIs
Date of Entire Project:	9/1/98 – 1/31/99
Total Costs:	\$59,026
Source:	National Institute of Mental Health
Role:	Investigator, Executive Committee Member
Title:	Mental Health Services for Woman in Public Medical Costs
Date of Entire Project:	7/1/98-8/31/99
Total Costs:	\$300,000
Source:	National Cancer Institute (Fox Chase Cancer Center subcontract)
Role:	Principal Investigator
Title:	Patient Decision Making in Phase I Cancer Clinical Trials
Date of Entire Project:	9/29/98-9/30/01
Total Costs:	\$418,240

Source: The Robert Wood Johnson Foundation
 Role: Principal Investigator
 Title: The Relationship between Market Forces and the Costs, Treatments and Outcomes of Medicare Patients
 Date of Entire Project: 1/1/99-6/30/01
 Total Costs: \$250,000

Source: National Heart, Lung, and Blood Institute (University of Washington subcontract)
 Role: Principal Investigator
 Title: Cardiovascular Health Study Claims Data Analysis
 Date of Entire Project: 11/1/99-10/31/01
 Total Costs: \$83,888

Source: Agency for Health Care Research and Quality (University of Arizona subcontract)
 Role: Investigator
 Title: Centers for Education and Research on Therapeutics (CERTs)
 Date of Entire Project: 9/30/99-9/29/02
 Total Costs: \$864,513

Source: Agency for Healthcare Research and Quality and Health Resources and Services Administration
 Role: Principal Investigator
 Title: 1998 through 2003 Annual NRSA Trainees Research Conference
 Date of Entire Project: 4/1/98-3/31/03
 Total Costs: \$557,699

Source: Durham VA Medical Center/Bristol Myers Squibb
 Role: Principal Investigator
 Title: CSP 442
 Date of Entire Project: 10/1/99-9/30/03
 Total Costs: \$200,816

Source: Agency for Healthcare Research and Quality and Health Resources and Services Administration
 Role: Principal Investigator
 Title: 2003 through 2008 Annual NRSA Trainees Conference
 Date of Entire Project: 4/1/03 – 3/31/04
 Total Costs: \$300,000

Source: National Heart, Lung, and Blood Institute
 Role: Principal Investigator
 Title: ACTION EQOL Study
 Date of Entire Project: 9/29/02-12/31/08
 Total Costs: \$2,602,524

Source: National Cancer Institute
 Role: Co-Investigator
 Title: Understanding Patient Expectations of Treatment Outcomes
 Date of Entire Project: 3/9/05-8/31/08
 Total Costs: \$1,319,007

Source: DHHS/AHRQ
 Role: Investigator
 Title: Research on Health Outcomes of Carotid Artery Disease (DEcIDE)
 Date of Entire Project: 10/16/07 – 1/15/09
 Total Costs: \$130,608

Source: National Institutes of Health
Role: Co – Investigator
Title: Disclosing Conflict of Interests to Research Study Participants
Date of Entire Project: 1/15/04-12/31/09
Total Costs: \$3,108,276

Source: National Institutes of Health
Role: Principal Investigator (9/28/04-5/19/05), Co-Investigator (5/20/05-7/31/09)
Title: PROMIS (independent study, network activity, and supplement)
Date of Entire Project: 9/28/04-7/31/09
Total Costs: \$6,439,367

Source: National Heart, Lung, and Blood Institute
Role: Principal Investigator
Title: Duke-UNC Sickle Cell Disease Clinical Research Network
Date of Entire Project: 4/17/06 – 3/31/11
Total Costs: \$772,956

Source: National Institutes of Health
Role: Co-Investigator
Title: Heart Failure and Epidemiology in the Elderly
Date of Entire Project: 8/1/06 – 7/31/09
Total Costs: \$998,506

Source: Wake Forest/NIH
Role: Co-Investigator
Title: Clinical Validity and Utility of Genomic Targeted Chemoprevention of Pca
Date of Entire Project: 9/29/09 – 8/31/12
Total Costs: \$511,258

Source: National Institutes of Health
Role: Co-Investigator
Title: TEAM HF
Date of Entire Project: 9/29/09 – 7/31/13
Total Costs: \$1,177,259

Source: FDA
Role: Principal Investigator
Title: Fellows Course
Date of Entire Project: 7/1/13 – 11/15/13
Total Costs: \$52,289

OTHER SUPPORT

ACTIVE

Industry Sponsored Research Studies Aggregated Effort 0.12 calendar

Duke University lists aggregated effort assigned to the following eligible industry-sponsored clinical trial projects. Each of these individual projects has a varying need of effort depending on the type of activity currently in progress: protocol development, start-up, patient recruitment, enrollment, follow-up, monitoring, data analysis, publication, and closeout. Faculty determines each project's need and adjust their effort between projects within the total aggregated effort assigned to the clinical projects.

DCRI #4734 (Hernandez) 05/01/09-01/15/19
Amylin Pharmaceuticals \$35,257,749
EXSCEL Cardiovascular Outcomes Study in Diabetes

This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.

DCRI (Schulman) 01/06/16 – 01/05/18
Humacyte Inc. \$259,114

Humacyte Study

Using personal identifiers provided from Visonex, DCRI will request linked Medicare claims from ResDAC from 2010 through 2014 (2014 claims expected to be available in December 2015) to provide a year of prior claims for detection of existing comorbidities and to determine Medicare eligibility.

NON-ACTIVE

Source: Fox Chase Cancer Center
Role: Principal Investigator
Title: Metastatic Breast Cancer Bone Marrow Transplant Program Cost Effective Analysis
Date of Entire Project: 7/1/92-6/30/96
Total Costs: \$260,000

Source: The Upjohn Company
Role: Principal Investigator
Title: Economic Analysis of Tirilazad Mesylate in Head Injury
Date of Entire Project: 9/01/92-6/30/97
Total Costs: \$137,500

Source: The Upjohn Company
Role: Principal Investigator
Title: Economic Analysis of Tirilazad in Subarachnoid Hemorrhage
Date of Entire Project: 9/01/92 -9/30/97
Total Costs: \$110,000

Source: The Upjohn Company
Role: Principal Investigator
Title: Economic Analysis of Protocol M/3331/0017 for the Use of Delavirdine Mesylate in HIV-Infected Patients
Date of Entire Project: 6/1/94 -6/30/98
Total Costs: \$242,500

Source: Amgen
Role: Principal Investigator
Title: NCI/ASCO Economics Conference
Date of Entire Project: 1/1/96-6/30/97
Total Costs: \$90,000

Source: Novartis Pharmaceuticals Corporation
Role: Principal Investigator
Title: Novartis Fellowship in Pharmacoeconomics (Boyko)
Date of Entire Project: 07/01/96-06/30/98
Total Costs: \$100,714

Source: Delmarva Foundation/HCF
Role: Principal Investigator
Title: National Cardiovascular Cooperative Project–Relation of SES Indicators to Types of Intervention and Outcome
Date of Entire Project: 10/01/96-12/31/97
Total Costs: \$73,009

Source:	Delmarva Foundation/HCF
Role:	Investigator
Title:	National Cardiovascular Cooperative Project–Primary Angioplasty versus Thrombolytic Therapy in the Management of Acute Myocardial Infarction
Date of Entire Project:	10/01/96-12/31/97
Total Costs:	\$62,463
Source:	The Bayer Corporation
Role:	Principal Investigator
Title:	Economic Analysis of Protocol “A Study of the Safety and Efficacy of Antithrombin in Patients with Heparin Resistance Undergoing Cardiopulmonary Bypass Surgery”
Date of Entire Project:	12/01/96-8/31/99
Total Costs:	\$125,000
Source:	The Bayer Corporation
Role:	Principal Investigator
Title:	Health Economic Study of AT III Treatment in the Management of Meningococcal Purpura Fulminans
Date of Entire Project:	4/1/97-8/31/99
Total Costs:	\$180,875
Source:	Novartis Pharmaceuticals
Role:	Principal Investigator
Title:	Novartis Fellowship/Shilpa Mehta
Date of Entire Project:	7/01/97-6/30/99
Total Costs:	\$101,604
Source:	Delmarva Foundation/HCF
Role:	Principal Investigator
Title:	National Cardiovascular Cooperative Project–Predictors of 30 Mortality in Diabetic Patients with Acute Myocardial Infarction
Date of Entire Project:	10/1/96-12/31/97
Total Costs:	\$80,004
Source:	G.D. Searle & Company
Role:	Principal Investigator
Title:	Economic Analysis of Protocol IG7-96-02-017 (EXCITE)
Date of Entire Project:	8/1/97-8/31/99
Total Costs:	\$284,375
Source:	G.D. Searle & Company
Role:	Principal Investigator
Title:	Economic Analysis of Protocol OPUS-TIMI-16
Date of Entire Project:	8/1/97 – 8/31/99
Total Costs:	\$244,375
Source:	Novartis Pharmaceuticals/US
Role:	Principal Investigator
Title:	AR/BC2 Clinical Trial using the Q-Twist Method
Date of Entire Project:	10/30/97-3/30/98
Total Costs:	\$90,000
Source:	Novartis Pharmaceuticals/US
Role:	Principal Investigator
Title:	The Burden of Illness of Irritable Bowel Syndrome in the United States
Date of Entire Project:	4/30/98-6/30/99
Total Costs:	\$262,500

Source: Bristol Myers Squibb
Role: Principal Investigator
Title: Costs of Incident Cholesterol Treatment
Date of Entire Project: 6/1/98-2/28/99
Total Costs: \$81,250

Source: Novartis Pharmaceuticals/US
Role: Principal Investigator
Title: Novartis Fellowship/Jennifer Kim
Date of Entire Project: 7/1/98-6/30/00
Total Costs: \$100,842

Source: Novartis Pharmaceuticals/US
Role: Principal Investigator
Title: A Randomized Trial of Treatment Guidelines in the Care of Patients with Metastatic Breast Cancer and Multiple Myeloma
Date of Entire Project: 7/1/98-12/31/99
Total Costs: \$296,250

Source: Novartis Pharmaceuticals/US
Role: Principal Investigator
Title: Evaluation of the Cost of Care and Treatment Practices Associated with Diabetic Foot Ulcers
Date of Entire Project: 11/1/98-6/30/99
Total Costs: \$35,000

Source: Novartis Pharmaceuticals/US
Role: Principal Investigator
Title: Economic Evaluation of Apligraf
Date of Entire Project: 12/1/99 – 6/30/00
Total Costs: \$125,000

Source: Novartis Pharmaceuticals/US
Role: Principal Investigator
Title: Novartis Fellowship/John Kim
Date of Entire Project: 7/1/99-6/30/01
Total Costs: \$101,418

Source: Yamanouchi USA Foundation
Role: Principal Investigator
Title: Yamanouchi Fellowship
Date of Entire Project: 12/1/97 -12/31/99
Total Costs: \$105,000

Source: Novartis Pharmaceuticals/Basel
Role: Principal Investigator
Title: Literature Review and Critique for the Ruffinamide Trial
Date of Entire Project: 9/20/00 – 9/29/00
Total Costs: \$5,978

Source: Pharmacia
Role: Principal Investigator
Title: Development of a Functional Assessment CRF Module for Metastatic Breast Cancer
Date of Entire Project: 1/22/01 – 2/28/01
Total Costs: \$22,021

Source: Kellogg Foundation

Role: Principal Investigator
 Title: The Effect of Immigration on the Costs of Hospital Care
 Date of Entire Project: 2/1/00 – 1/31/02
 Total Costs: \$35,000

Source: Boston Scientific Corporation
 Role: Principal Investigator
 Title: Treatment Patterns and Costs Associated with Sessile Colorectal Lesions
 Date of Entire Project: 9/1/00 – 1/31/01
 Total Costs: \$ 79,610

Source: Novartis Pharmaceuticals/Basel
 Role: Principal Investigator
 Title: International Costing Study/ALERT and LIPS
 Date of Entire Project: 6/1/00 – 9/30/01
 Total Costs: \$ 75,000

Source: Novartis Pharmaceuticals/US
 Role: Principal Investigator
 Title: Managing Antiepileptic Drug Treatment in Emergency Care Settings
 Date of Entire Project: 10/31/00 – 6/30/01
 Total Costs: \$ 25,175

Source: Novartis Pharmaceuticals/Basel
 Role: Principal Investigator
 Title: Economic Evaluation of ValHeft
 Date of Entire Project: 7/1/00 – 4/30/01
 Total Costs: \$ 298,172

Source: Novartis Pharmaceuticals/Basel
 Role: Principal Investigator
 Title: International Costing Study for ValHeft
 Date of Entire Project: 4/1/00 – 11/30/00
 Total Costs: \$ 60,000

Source: Novartis Pharmaceuticals/US
 Role: Principal Investigator
 Title: Novartis Fellowship/Veronica Sendersky
 Date of Entire Project: 7/1/00 -6/30/02
 Total Costs: \$105,377

Source: Novartis Pharmaceuticals/US
 Role: Principal Investigator
 Title: The Economic Impact of Congestive Heart Failure and Heart Failure Therapies: A Review of the Literature and Development of a Speaker Slide Kit
 Date of Entire Project: 2/1/01 -8/31/01
 Total Costs: \$65,148

Source: Novartis Pharmaceuticals/US
 Role: Principal Investigator
 Title: Elicitation of Parent Preferences for Atopic Dermatitis in Children
 Date of Entire Project: 6/1/01 – 11/30/01
 Total Costs: \$127,024

Source: Novartis Pharmaceuticals/US

Role:	Principal Investigator
Title:	Budget Impact for Elidel
Date of Entire Project:	7/1/01 – 8/17/01
Total Costs:	\$36,600
Source:	Novartis/Basel
Role:	Principal Investigator
Title:	Analyzing Treatment Patterns for Major Adverse Cardiac Events (MACE) Across International Countries
Date of Entire Project:	6/1/01 – 9/30/01
Total Costs:	\$3,447
Source:	Pharmacia
Role:	Principal Investigator
Title:	A New Functional Assessment CRF Module for Peripheral Neuropathy Induced by Chemotherapy: A Pilot Validation Study in Patients with Metastatic Breast Cancer and Small Cell Lung Cancer
Date of Entire Project:	6/1/01 – 9/30/01
Total Costs:	\$30,683
Source:	Novartis/Basel
Role:	Principal Investigator
Title:	Feasibility Study of Pitavastatin
Date of Entire Project:	10/1/01 – 11/22/01
Total Costs:	\$20,000
Source:	Novartis/Basel
Role:	Principal Investigator
Title:	Feasibility Study of Navigator
Date of Entire Project:	10/1/01 – 11/22/01
Total Costs:	\$28,000
Source:	Pharmacia
Role:	Principal Investigator
Title:	LEP Manuscript
Date of Entire Project:	10/22/01 – 11/22/01
Total Costs:	\$15,588
Source:	Novartis/Canada
Role:	Principal Investigator
Title:	Canadian Adaptation of ValHeFT
Date of Entire Project:	11/01 – 12/21/01
Total Costs:	\$19,951
Source:	Novartis Pharmaceuticals/Canada
Role:	Principal Investigator
Title:	Canadian Adaptation of Zoledronate Economic Analysis
Date of Entire Project:	6/1/01 – 11/30/01
Total Costs:	\$32,269
Source:	Novartis Pharmaceuticals
Role:	Principal Investigator
Title:	Economic Impact of CHF
Date of Entire Project:	6/1/01 – 9/31/01
Total Costs:	\$65,148
Source:	Novartis Pharmaceuticals/Canada

Role:	Principal Investigator
Title:	Canadian Adaptation of the Micro-Costing Model
Date of Entire Project:	1/1/01 – 4/30/01
Total Costs:	\$23,058
Source:	Novartis Pharmaceuticals/Netherlands
Role:	Principal Investigator
Title:	Netherlands Adaptation of ValHeft
Date of Entire Project:	2/1/02 – 3/31/02
Total Costs:	\$12,172
Source:	Novartis Pharmaceuticals/Belgium
Role:	Principal Investigator
Title:	Belgian Adaptation of ValHeft
Date of Entire Project:	2/1/02 – 3/31/02
Total Costs:	\$12,172
Source:	Novartis Pharmaceuticals/Germany
Role:	Principal Investigator
Title:	German Adaptation of ValHeft
Date of Entire Project:	10/1/02 – 11/27/02
Total Costs:	\$13,648
Source:	Novartis/Basel
Role:	Principal Investigator
Title:	Economic Analysis of RADB-253
Date of Entire Project:	11/2/01 – 12/31/02
Total Costs:	\$127,081
Source:	Novartis Pharmaceuticals/Basel
Role:	Principal Investigator
Title:	Assess Investigator and Site Characteristics for Participating Navigator Centers
Date of Entire Project:	7/16/01 – 3/31/03
Total Costs:	\$68,503
Source:	Purdue Pharmaceuticals
Role:	Principal Investigator
Title:	A Review of the Depression Literature as a Framework for the Cost of Pain
Date of Entire Project:	10/1/02 – 11/30/02
Total Costs:	\$25,050
Source:	Novartis Pharmaceuticals
Role:	Principal Investigator
Title:	The Impact of Cytomegalovirus Infection on Within-Trial Costs in RADB-253
Date of Entire Project:	10/21/02 – 1/15/03
Total Costs:	\$25,468
Source:	Novartis Pharmaceuticals/US
Role:	Principal Investigator
Title:	Economic Analysis of Zoledronate (Protocol 039)
Date of Entire Project:	5/98-6/03
Total Costs:	\$559,033
Source:	Yamanouchi USA Foundation
Role:	Principal Investigator
Title:	Yamanouchi Fellowship
Date of Entire Project:	1/1/01 -12/31/03
Total Costs:	\$191,232

Source:	Novartis Pharmaceuticals/US
Role:	Principal Investigator
Title:	Novartis Fellowship/Amy Law
Date of Entire Project:	7/1/01 -6/30/03
Total Costs:	\$104,461
Source:	Novartis Pharmaceuticals/Basel
Role:	Principal Investigator
Title:	QOL and Economic Evaluation of Protocol 4244603010
Date of Entire Project:	7/17/00 – 8/31/03
Total Costs:	\$250,000
Source:	Novartis/Basel
Role:	Principal Investigator
Title:	Gleevec
Date of Entire Project:	9/1/01 – 6/30/03
Total Costs:	\$290,385
Source:	Ernst and Young
Role:	Principal Investigator
Title:	Project in Collaboration with Health Sector Management
Date of Entire Project:	1/2/02 – 12/31/02
Total Costs:	\$77,958
Source:	Bristol Myers Squibb
Role:	Principal Investigator
Title:	MMPI
Date of Entire Project:	2/22/01 – 5/31/03
Total Costs:	\$ 151,221
Source:	Novartis Pharmaceuticals/Basel
Role:	Principal Investigator
Title:	Horizon Hip Fracture Study
Date of Entire Project:	1/1/2002 – 5/31/03
Total Costs:	\$108,927
Source:	Novartis Pharmaceuticals/US
Role:	Principal Investigator
Title:	Survey of Unmet Needs and Preferences of Patients with Osteoarthritis
Date of Entire Project:	8/1/02 – 5/1/03
Total Costs:	\$146,823
Source:	Wyeth Pharmaceuticals
Role:	Principal Investigator
Title:	Treatment Patterns, Process of Care and Estimated Costs Associated with Treating Subsets of Patients with Sepsis
Date of Entire Project:	9/1/02 – 4/30/03
Total Costs:	\$75,000
Source:	Novartis Pharmaceuticals
Role:	Principal Investigator
Title:	Analysis of Resource Utilization and Costs Among Spanish Patients with Moderate to Severe Alzheimer's Disease Randomized to Exelon or Placebo.
Date of Entire Project:	11/4/02 – 5/15/03
Total Costs:	\$7,530
Source:	Novartis Pharmaceuticals/Basel

Role:	Principal Investigator
Title:	Quality of Life Data Evaluation Protocol 4244603011
Date of Entire Project:	7/17/00 – 12/31/03
Total Costs:	\$75,000
Source:	Novartis Pharmaceuticals/Basel
Role:	Principal Investigator
Title:	Monitoring Quality of Life and Resource Use Data for VALIANT
Date of Entire Project:	7/1/01 – 12/31/03
Total Costs:	\$59,475
Source:	Novartis/Basel
Role:	Principal Investigator
Title:	Additional Analysis Required for Manuscript Preparation on Protocols 039, 010,011
Date of Entire Project:	10/1/01 – 12/31/03
Total Costs:	\$42,403
Source:	Novartis Pharmaceuticals/Basel
Role:	Principal Investigator
Title:	Monitoring Quality of Life and Resource Use Data for VALUE
Date of Entire Project:	7/16/01 – 12/31/03
Total Costs:	\$52,537
Source:	Novartis Pharmaceuticals
Role:	Principal Investigator
Title:	Economic Analysis of Valsartan in High Risk Patients After Acute Myocardial Infarction
Date of Entire Project:	8/22/02 – 6/30/04
Total Costs:	\$204,271
Source:	Novartis Pharmaceuticals
Role:	Principal Investigator
Title:	VALIANT – Multinational Conference
Date of Entire Project:	5/1/03 – 12/31/03
Total Costs:	\$50,000
Source:	Johnson and Johnson
Role:	Principal Investigator
Title:	Fellowship in Outcomes Research (Raisel)
Date of Entire Project:	7/1/03 – 6/30/04
Total Costs:	\$115,341
Source:	Kellogg Foundation
Role:	Principal Investigator
Title:	Health Workforce Diversity Assessment
Date of Entire Project:	6/1/03 – 5/31/04
Total Costs:	\$50,000
Source:	Kellogg Foundation
Role:	Principal Investigator
Title:	Literature Review and Economic Impact of Diversification
Date of Entire Project:	6/1/03 – 5/31/04
Total Costs:	\$120,000
Source:	Novartis Pharmaceuticals
Role:	Principal Investigator
Title:	Cost of Acute Myocardial Infarction in the New Millennium
Date of Entire Project:	10/15/02 – 7/31/03
Total Costs:	\$125,000

Source:	Novartis Pharmaceuticals/US
Role:	Principal Investigator
Title:	Novartis Fellowship/Jane Chang
Date of Entire Project:	7/1/02 -12/31/04
Total Costs:	\$105,302
Source:	Duke Endowment
Role:	Co- Principal Investigator
Title:	Center to Reduce Racial Disparities
Date of Entire Project:	1/1/02 – 12/31/04
Total Costs:	\$529,684
Source:	Novartis Pharmaceuticals/Basel
Role:	Principal Investigator
Title:	Data Monitoring for Horizon
Date of Entire Project:	2/1/02 – 3/31/05
Total Costs:	\$61,613
Source:	Bristol Myers Squibb
Role:	Principal Investigator
Title:	BMS 014
Date of Entire Project:	7/1/03 – 12/31/04
Total Costs:	\$ 131,453
Source:	Johnson and Johnson
Role:	Principal Investigator
Title:	Economic Analysis and Quality of Life Study of Epoetin Alfa
Date of Entire Project:	12/1/03 – 4/30/05
Total Costs:	\$270,512
Source:	Pfizer Health Solutions
Role:	Principal Investigator
Title:	Florida: A Healthy State Initiative – Peer Reviewed White Paper
Date of Entire Project:	5/1/04 – 9/30/04
Total Costs:	\$112,939
Source:	Novartis Pharmaceuticals
Role:	Principal Investigator
Title:	Economic Analysis Alongside the Navigator Trial
Date of Entire Project:	12/1/03 – 12/31/04
Total Costs:	\$30,000
Source:	Amgen
Role:	Principal Investigator
Title:	CD – ROM
Date of Entire Project:	11/17/04 – 5/31/05
Total Costs:	\$174,901
Source:	Genentech
Role:	Principal Investigator
Title:	Cost of Drug Development
Date of Entire Project:	12/15/04 – 5/31/05
Total Costs:	\$220,964
Source:	North Carolina Biotechnology Center
Role:	Co-Principal Investigator
Title:	NC-Omics

Date of Entire Project:	8/1/04 – 1/31/05
Total Costs:	\$30,000
Source:	Novartis Pharmaceuticals
Role:	Principal Investigator
Title:	Fellowship in Outcomes Research/Mahajan
Date of Entire Project:	7/1/03 – 11/30/05
Total Costs:	\$149,761
Source:	Novartis Pharmaceuticals
Role:	Principal Investigator
Title:	Outcomes Research Fellowship/Phyllis Perkins
Date of Entire Project:	7/1/05 – 11/30/05
Total Costs:	\$23,491
Source:	Johnson and Johnson Orthobiotech
Role:	Principal Investigator
Title:	Fellowship in Outcomes Research/ Kathryn Flynn
Date of Entire Project:	9/1/05 – 8/31/06
Total Costs:	\$112,787
Source:	Novartis Pharmaceuticals
Role:	Principal Investigator
Title:	Outcomes Research Fellowship/William Grant
Date of Entire Project:	6/1/04 – 5/31/06
Total Costs:	\$111,013
Source:	Johnson and Johnson Orthobiotech
Role:	Principal Investigator
Title:	Fellowship in Outcomes Research/ John Villani
Date of Entire Project:	7/1/05 – 6/30/06
Total Costs:	\$115,341
Source:	Kureha Pharmaceuticals
Role:	Principal Investigator
Title:	Fellowship
Date of Entire Project:	10/1/04 – 9/30/06
Total Costs:	\$155,276
Source:	Actelion Pharmaceuticals
Role:	Principal Investigator
Title:	TRACLEER
Date of Entire Project:	4/1/05 – 6/15/05
Total Costs:	\$117,801
Source:	Actelion Pharmaceuticals
Role:	Principal Investigator
Title:	Vasospasm
Date of Entire Project:	4/1/05 – 6/15/05
Total Costs:	\$51,015
Source:	Novartis Pharmaceuticals
Role:	Co-Investigator
Title:	B-Cell Function and Costs
Date of Entire Project:	4/13/05 – 1/31/06
Total Costs:	\$149,720
Source:	Novartis Pharmaceuticals

Role:	Co-Investigator
Title:	Medicare Modernization
Date of Entire Project:	12/1/04 – 2/28/06
Total Costs:	\$174,508
Source:	Nabi Biopharmaceuticals
Role:	Principal Investigator
Title:	Staphvax
Date of Entire Project:	7/1/03 – 6/30/06
Total Costs:	\$301,280
Source:	Sanofi – Aventis Pharmaceuticals
Role:	Co- Investigator
Title:	Metabolic Syndrome in the Elderly
Date of Entire Project:	11/8/05 – 5/31/06
Total Costs:	\$206,101
Source:	Allergan Pharmaceuticals
Role:	Co- Investigator
Title:	Descriptive Analysis – Macular Edema
Date of Entire Project:	4/1/05 – 4/30/06
Total Costs:	\$131,051
Source:	National Patient Advocate Foundation/Eli Lilly
Role:	Principal Investigator
Title:	The Medicare Modernization Act and Changes in Reimbursement for Outpatient Chemotherapy: Do Patients Perceive Changes in Access to Care?
Date of Entire Project:	1/1/06 – 9/30/06
Total Costs:	\$270,000
Source:	Bristol Myers Squibb
Role:	Principal Investigator
Title:	Economic and PRO Analysis of Erbitux for Colorectal Cancer Economic Analysis (BMS 006)
Date of Entire Project:	6/1/02 – 6/30/07
Total Costs:	\$250,000
Source:	Actelion Pharmaceuticals
Role:	Principal Investigator
Title:	Compass II
Date of Entire Project:	10/18/05 – 8/31/07
Total Costs:	\$573,453
Source:	Actelion Pharmaceuticals
Role:	Co- Investigator
Title:	Burden of Illness for PAH
Date of Entire Project:	10/1/05 – 8/31/07
Total Costs:	\$241,998
Source:	Actelion Pharmaceuticals
Role:	Co- Investigator
Title:	Cost of Vasospasm in Patients with Aneurysmal SAH
Date of Entire Project:	10/1/05 – 4/30/07
Total Costs:	\$228,850
Source:	Sanofi – Aventis Pharmaceuticals
Role:	Co- Investigator
Title:	Hyponatremia
Date of Entire Project:	6/1/06 – 4/30/07

Total Costs:	\$89,933
Source:	Novartis Pharmaceuticals
Role:	Co-Investigator
Title:	Updating the Gleevec Model
Date of Entire Project:	3/1/06 – 9/30/06
Total Costs:	\$180,820
Source:	Sanofi – Aventis Pharmaceuticals
Role:	Co- Investigator
Title:	Validity of Hyponatremia ICD coding and Impact of Hyponatremia in the Elderly
Date of Entire Project:	10/20/06 – 4/30/07
Total Costs:	\$154,736
Source:	National Patient Advocate Foundation/Eli Lilly
Role:	Principal Investigator
Title:	The Medicare Modernization Act and Access to Care for Cancer Patients Receiving Intravenous Chemotherapy
Date of Entire Project:	1/1/07 – 9/30/07
Total Costs:	\$164,592
Source:	Amgen
Role:	Principal Investigator
Title:	Panel Discussion of Follow-On Biologics Approval Process
Date of Entire Project:	6/1/07 – 6/30/07
Total Costs:	\$60,000
Source:	Allergan
Role:	Co-Investigator
Title:	Applying and Extending a Claims Based Algorithm for Diabetic Macular Edema
Date of Entire Project:	3/1/06 – 8/31/07
Total Costs:	\$140,952
Source:	Bristol Myers Squibb
Role:	Principal Investigator
Title:	BMS 048
Date of Entire Project:	2/1/04 – 4/30/08
Total Costs:	\$94,521
Source:	Bristol Myers Squibb
Role:	Co- Investigator
Title:	Development of an Economic Model for the Use of Ixabepilone in Advanced Breast Cancer
Date of Entire Project:	6/1/05 – 4/30/08
Total Costs:	\$185,786
Source:	Bristol Myers Squibb
Role:	Co- Investigator
Title:	Economic Analysis of Protocol 081
Date of Entire Project:	10/1/06 – 4/30/08
Total Costs:	\$88,252
Source:	Vertex
Role:	Co- Investigator
Title:	Development of a Markov Model Evaluating the Impact of VX-950 on the Cost Effectiveness of Antiviral Therapy for Patients with Chronic HCV Infection
Date of Entire Project:	1/1/07 – 12/31/07
Total Costs:	\$75,000

Source:	Bristol Myers Squibb
Role:	Principal Investigator
Title:	Epothilone 046/Symptom Assessment
Date of Entire Project:	11/1/03 – 5/31/08
Total Costs:	\$305,906
Source:	Novartis Pharmaceuticals
Role:	Principal Investigator
Title:	Outcomes Research Fellowship/Chia Hung Chou
Date of Entire Project:	10/1/06 – 5/31/08
Total Costs:	\$113,575
Source:	Medtronic Inc.
Role:	Co-Investigator
Title:	Heart Failure in the Elderly: and Epidemiology and Treatment
Date of Entire Project:	12/1/06 – 1/31/08
Total Costs:	\$119,195
Source:	Thomson Health Care
Role:	Principal Investigator
Title:	Program for Case Study, Presentation and Group Discussion
Date of Entire Project:	11/1/07 – 6/30/08
Total Costs:	\$100,000
Source:	Allergan
Role:	Co Investigator
Title:	Cost of Illness Associated with Retinal Vein Occlusion (RVO)
Date of Entire Project:	11/1/07 – 5/31/08
Total Costs:	\$148,199
Source:	Astellas Pharmaceuticals
Role:	Co-Investigator
Title:	Analysis of Candida Infections: An Analysis of the Economic and Clinical Evaluation of Microbiology Cultures (ECEMC) Database
Date of Entire Project:	\$100,452
Total Costs:	7/1/07 – 9/30/08
Source:	Medtronic Inc.
Role:	Co- Investigator
Title:	Implantable Cardioverter Defibrillators in the Elderly: Processes of Care and Predictors of Use
Date of Entire Project:	5/1/07 – 7/31/08
Total Costs:	\$110,988
Source:	Tengion, Inc.
Role:	Principal Investigator
Title:	Unrestricted Fellowship for Chuck Scales
Date of Entire Project:	11/1/07 – 10/31/08
Total Costs:	\$50,000
Source:	Allergan
Role:	Co Investigator
Title:	Cost of Illness Associated with Low Vision Literature Search and Review
Date of Entire Project:	7/1/08 – 8/31/08
Total Costs:	\$39,056
Source:	Duke University School of Medicine
Role:	Co-Investigator

Title:	IMDMI
Date of Entire Project:	3/1/05 – 4/30/09
Total Costs:	\$409,209
Source:	OSI Eyetech
Role:	Co-Investigator
Title:	Longitudinal Analysis of Age-Related Macular Degeneration and Diabetic Retinopathy in the Elderly: Treatment and Outcomes
Date of Entire Project:	\$296,156
Total Costs:	4/1/07 – 3/09
Source:	Theravance
Role:	Principal Investigator
Title:	Economic Evaluation of Telavancin vs. Vancomycin for Treatment of Hospital Acquired Pneumonia
Date of Entire Project:	11/1/04 – 7/31/09
Total Costs:	\$500,000
Source:	Medtronic MiniMed
Role:	Principal Investigator
Title:	Insulin Pump Study
Date of Entire Project:	6/1/06 – 12/31/09
Total Costs:	\$253,325
Source:	Inspire
Role:	Principal Investigator
Title:	Economic and Quality of Life Evaluation of Denufosol (INS37217) Inhalation Solution in Patients with Mild Cystic Fibrosis Lung Disease (TIGER 1)
Date of Entire Project:	4/1/06- 8/1/09
Total Costs:	\$279,517
Source:	NovaCardia, Inc.
Role:	Co-Investigator
Title:	PROTECT
Date of Entire Project:	7/1/06 – 10/1/09
Total Costs:	\$581,738
Source:	Arthritis Foundation
Role:	Co- Investigator
Title:	Cost Effectiveness of Biologics for RA in Clinical Practice
Date of Entire Project:	7/1/06 – 6/30/10
Total Costs:	\$600,000
Source:	Inspire
Role:	Co Investigator
Title:	Economic and Quality of Life Evaluation of Denufosol (INS37217) Inhalation Solution in Patients with Mild Cystic Fibrosis Lung Disease (Protocol 08-110, TIGER 2)
Date of Entire Project:	1/1/08 – 7/31/10
Total Costs:	\$307,142
Source:	The Duke Endowment
Role:	Principal Investigator
Title:	Personal Health Record Pilot Project at the Duke Heart Center
Date of Entire Project:	7/1/08 – 6/30/09
Total Costs:	\$600,000
Source:	Merck
Role:	Principal Investigator

Title:	Staph Aureus
Date of Entire Project:	1/1/08 – 12/31/09
Total Costs:	\$571,015
Source:	Duke University School of Medicine/GME
Role:	Principal Investigator
Title:	A web based, pod cast: Healthcare Policy and Leadership Lecture Series
Date of Entire Project:	1/1/08 – 12/31/09
Total Costs:	\$101,741
Source:	Duke University School of Medicine/GME
Role:	Principal Investigator
Title:	Critical Content, Creative Delivery and Collaboration
Date of Entire Project:	7/1/09 – 6/30/10
Total Costs:	\$61,000
Source:	Glaxo Smith Kline
Role:	Co -Investigator
Title:	ARMD Cost of Illness
Date of Entire Project:	11/1/09 – 6/1/11
Total Costs:	\$215,413
Source:	Glaxo Smith Kline
Role:	Co -Investigator
Title:	ARMD
Date of Entire Project:	5/1/09 – 11/30/10
Total Costs:	\$149,393
Source:	J&J
Role:	Principal Investigator
Title:	Adhere III
Date of Entire Project:	9/1/09 – 9/10/10
Total Costs:	\$534,136
Source:	Scios
Role:	Co Investigator
Title:	ASCEND
Date of Entire Project:	7/1/08 – 9/30/11
Total Costs:	\$718,287
Source:	Duke University School of Medicine/GME
Role:	Principal Investigator
Title:	Health Policy Content: Just in Time
Date of Entire Project:	7/1/10 – 6/30/13
Total Costs:	\$152,225
Source:	Verizon
Role:	Principal Investigator
Title:	HRA
Date of Entire Project:	7/1/11 – 11/30/12
Total Costs:	\$175,859
Source:	Novartis
Role:	Co-Investigator
Title:	Development of Preliminary Economic Parameters in Early Detection of Healthcare Associated Infections in the Intensive Care Unit Using the Host Response
Date of Entire Project:	10/1/10 – 9/30/13
Total Costs:	\$238,963

Source: Verizon
 Role: Principal Investigator
 Title: Transformative Health Information Technology Initiatives
 Date of Entire Project: 7/1/11 – 6/30/14
 Total Costs: \$300,000

Source: Janssen
 Role: Principal Investigator
 Title: ASPEN
 Date of Entire Project: 1/1/13 – 7/31/15
 Total Costs: \$1,357,377

BIBLIOGRAPHY

ORIGINAL RESEARCH ARTICLES:

1. Green J, Singer M, Wintfeld N, Schulman K, Passman L. Projecting the impact of AIDS on hospitals. *Health Aff (Millwood)*. 1987;6:19-31.
2. Green J, Singer M, Wintfeld N, Schulman K. AIDS in New England hospitals. *N Engl J Public Policy*. 1987;4(special issue):273-283.
3. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. *JAMA*. 1990;264:3025-3033.
4. Schulman KA, Glick HA, Rubin H, Eisenberg JM. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis: economic assessment of a new therapeutic agent. *JAMA*. 1991;266:3466-3471.
5. Greco PJ, Schulman KA, Lavizzo-Mourey R, Hansen-Flaschen J. The Patient Self-Determination Act and the future of advance directives. *Ann Intern Med*. 1991;115:639-643.
6. Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. *Ann Intern Med*. 1991;114:798-802.
7. Lynn LA, Schulman KA, Eisenberg JM. The pharmacoeconomics of HIV disease. *Pharmacoeconomics*. 1992;1:161-174.
8. Schulman KA, Escarce JJ, Eisenberg JM, et al. Assessing physicians' estimates of the probability of coronary artery disease: the influence of patient characteristics. *Med Decis Making*. 1992;12:109-114.
9. Seltzer E, Schulman KA, Brennan PJ, Lynn LA. Patient attitudes toward rooming with persons with HIV infection. *J Fam Pract*. 1993;37:564-568.
10. Schulman KA, McDonald RC, Lynn LA, Frank I, Christakis NA, Schwartz JS. Screening surgeons for HIV infection: assessment of a potential public health program. *Infect Control Hosp Epidemiol*. 1994;15:147-155.
11. Schulman K, Sulmasy DP, Roney D. Ethics, economics, and the publication policies of major medical journals. *JAMA*. 1994;272:154-156.
12. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA. Patient preferences for stroke outcomes. *Stroke*. 1994;25:1721-1725.
13. Roulidis ZC, Schulman KA. Physician communication in managed care organizations: opinions of primary care physicians. *J Fam Pract*. 1994;39:446-451.
14. Schulman KA, Glick HA. Economic evaluation of high-dose chemotherapy and bone marrow transplantation for patients with breast cancer of stage II or IIIA with more than 10 positive lymph nodes at surgical excision. *J Natl Cancer Inst Monogr*. 1995;(19):45-50.
15. Lee JH, Glick HA, Kinosian B, Schulman KA. An interactive computer system for formulary management using cost-effectiveness analysis. *MD Comput*. 1995;12:59-65.
16. Morris CB, Schulman KA. The emerging role of the Food and Drug Administration in pharmacoeconomic evaluation during the drug development process. *Drug Inf J*. 1995;29:1105-1111.
17. Schulman KA, Yabroff KR, Glick H. A health services approach for the evaluation of innovative pharmaceutical and biotechnology products. *Drug Inf J*. 1995;29:1405-1414.
18. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. *JAMA*. 1996;275:1885-1892.
19. Hirsh JA, Langlotz CP, Lee J, Tanio CP, Grossman RI, Schulman KA. Clinical assessment of MR of the brain in nonsurgical patients. *Am J Neuroradiol*. 1996;17:1245-1253.

20. Schulman KA, Glick H, Buxton M, et al. The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial. *Control Clin Trials*. 1996;17:304-315.
21. Knollmann BC, Corson AP, Twigg HL, Schulman KA. Assessment of joint review of radiologic studies by a primary care physician and a radiologist. *J Gen Intern Med*. 1996;11:608-612.
22. Schulman KA, Buxton M, Glick H, et al. Results of the economic evaluation of the FIRST study: a multinational prospective economic evaluation. Flolan International Randomized Survival Trial. *Int J Technol Assess Health Care*. 1996;12:698-713.
23. DeChant HK, Tohme WG, Mun SK, Hayes WS, Schulman KA. Health systems evaluation of telemedicine: a staged approach. *Telemed J*. 1996;2:303-312.
24. Mauskopf J, Schulman K, Bell L, Glick H. A strategy for collecting pharmacoeconomic data during phase II/III clinical trials. *Pharmacoeconomics*. 1996;9:264-277.
25. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. *BMJ*. 1996;313:275-283.
26. Schulman KA, Rubenstein LE, Seils DM, Harris M, Hadley J, Escarce JJ. Quality assessment in contracting for tertiary care services by HMOs: a case study of three markets. *Jt Comm J Qual Improv*. 1997;23:117-127.
27. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. *Health Econ*. 1997;6:243-252.
28. Mitchell JM, Meehan KR, Kong J, Schulman KA. Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors. *J Clin Oncol*. 1997;15:2644-2651.
29. Wasserfallen JB, Gold K, Schulman KA, Baraniuk JN. Development and validation of a rhinoconjunctivitis and asthma symptom score for use as an outcome measure in clinical trials. *J Allergy Clin Immunol*. 1997;100:16-22.
30. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). *Am Heart J*. 1997;134:44-54.
31. Roulidis ZC, DeChant HK, Schulman KA. Resource utilization control processes as indicators of quality in managed care organizations: a proposal. *Am J Med*. 1997;103:146-151.
32. Winchester JF, Tohme WG, Schulman KA, et al. Hemodialysis patient management by telemedicine: design and implementation. *ASAIO J*. 1997;43:M763-M766.
33. Tohme WG, Winchester JF, Collmann J, et al. Remote management of haemodialysis patients: design and implementation of a telemedicine network. *Minim Invasive Ther Allied Technol*. 1997;5/6:421-428.
34. Gaskin DJ, Kong J, Meropol NJ, Yabroff KR, Weaver C, Schulman KA. Treatment choices by seriously ill patients: the Health Stock Risk Adjustment model. *Med Decis Making*. 1998;18:84-94.
35. Glick HA, Polsky D, Willke RJ, Alves WM, Kassell N, Schulman K. Comparison of the use of medical resources and outcomes in the treatment of aneurysmal subarachnoid hemorrhage between Canada and the United States. *Stroke*. 1998;29:351-358.
36. Glick H, Willke R, Polsky D, et al. Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage: economic evaluation of a phase III clinical trial in Europe and Australia. *Int J Technol Assess Health Care*. 1998;14:145-160.
37. Sulmasy DP, Linas BP, Gold KF, Schulman KA. Physician resource use and willingness to participate in assisted suicide. *Arch Intern Med*. 1998;158:974-978.
38. Schulman KA, Dorsainvil D, Yabroff KR, et al. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. *Bone Marrow Transplant*. 1998;21:607-614.
39. Neymark N, Kiebert W, Torfs K, et al. Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop. *Eur J Cancer*. 1998;34:1317-1333.
40. Schulman K, Burke J, Drummond M, et al. Resource costing for multinational neurologic clinical trials: methods and results. *Health Econ*. 1998;7:629-638.
41. Rathore SS, Mehta SS, Boyko WL Jr, Schulman KA. Prescription medication use in older Americans: a national report card on prescribing. *Fam Med*. 1998;30:733-739.
42. Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. *Health Econ*. 1998;7:481-493.
43. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. *N Engl J Med*. 1999;340:618-626.
44. Schulman KA, Yabroff KR, Kong J, et al. A claims data approach to defining an episode of care. *Health Serv Res*. 1999;34:603-621.
45. De Jonge KE, Sulmasy DP, Gold KG, et al. The timing of do-not-resuscitate orders and hospital costs. *J Gen Intern Med*. 1999;14:190-192.

46. Boyko WL Jr, Glick HA, Schulman KA. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. ACE inhibitors in the management of congestive heart failure: comparative economic data. *Am Heart J*. 1999;137:S115-S119.
47. Schulman KA, Birch R, Zhen B, Pania N, Weaver CH. Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. *J Clin Oncol*. 1999;17:1227-1233.
48. Berger AK, Schulman KA, Gersh BJ, et al. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients. *JAMA*. 1999;282:341-348.
49. Schulman KA, Abernethy DR, Rathore SS, Woosley RL. Regulating manufacturer-affiliated communication in the information age. *Clin Pharmacol Ther*. 1999;65:593-597.
50. Wasserfallen JB, Gold K, Schulman KA, Baraniuk JN. Item responsiveness of a rhinitis and asthma symptom score during a pollen season. *J Asthma*. 1999;36:459-465.
51. Weinfurt KP, Willke R, Glick HA, Schulman KA. Towards a composite scoring solution for the Neurobehavioral Functioning Inventory. *Qual Life Res*. 1999;8:17-24.
52. Mehta SS, Wilcox CS, Schulman KA. Treatment of hypertension in patients with comorbidities: results from the study of hypertensive prescribing practices (SHyPP). *Am J Hypertens*. 1999;12(4 Pt 1):333-340.
53. Mehta SS, Suzuki S, Glick HA, Schulman KA. Determining an episode of care using claims data: diabetic foot ulcer. *Diabetes Care*. 1999;22:1110-1115.
54. Glick HA, Polsky D, Willke RJ, Schulman KA. A comparison of preference assessment instruments used in a clinical trial: responses to the visual analog scale from the EuroQol EQ-5D and the Health Utilities Index. *Med Decis Making*. 1999;19:265-275.
55. Freeman VG, Rathore SS, Weinfurt KP, Schulman KA, Sulmasy DP. Lying for patients: physician deception of third-party payers. *Arch Intern Med*. 1999;159:2263-2270.
56. Schulman KA, Mehta SS, Gersh BJ, Schneider EC, Wilcox CS. Study of Hypertensive Prescribing Practices (SHyPP): a national survey of primary care physicians. *J Clin Hypertens*. 1999;1:106-114.
57. Bentham WD, Cai L, Schulman KA. Characteristics of hospitalizations of HIV-infected patients: an analysis of data from the 1994 Healthcare Cost and Utilization Project. *JAIDS*. 1999;22:503-508.
58. Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. *J Clin Oncol*. 2000;18:43-53.
59. Cheng JD, Hitt J, Koczwara B, et al. Impact of quality of life on patient expectations regarding phase I clinical trials. *J Clin Oncol*. 2000;18:421-428.
60. Rathore SS, Berger AK, Weinfurt KP, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly : prevalence and outcomes. *Circulation*. 2000;101:969-974.
61. Weinfurt KP, Willke RJ, Glick HA, Freimuth WW, Schulman KA. Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. *Med Care*. 2000;38:404-410.
62. Rathore SS, Lenert LA, Weinfurt KP, et al. The effects of patient sex and race on medical students' ratings of quality of life. *Am J Med*. 2000;108:561-566.
63. Every NR, Maynard C, Schulman K, Ritchie JL. The association between institutional primary angioplasty procedure volume and outcome in elderly Americans. *J Invasive Cardiol*. 2000;12:303-308.
64. Mandelblatt JS, Hadley J, Kerner JF, et al. Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. *Cancer*. 2000;89:561-573.
65. Rathore SS, McGreevey JD, Schulman KA, Atkins D. Mandated coverage for cancer-screening services (2). Whose guidelines do states follow? *Am J Prev Med*. 2000;19:71-78.
66. Meehan KR, Matias CO, Rathore SS, et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. *Am J Hematol*. 2000;64:251-256.
67. Rathore SS, Berger AK, Weinfurt KP, et al. Race, sex, poverty, and the medical treatment of acute myocardial infarction in the elderly. *Circulation*. 2000;102:642-648.
68. Sheifer SE, Rathore SS, Gersh BJ, et al. Time to presentation with acute myocardial infarction in the elderly : associations with race, sex, and socioeconomic characteristics. *Circulation*. 2000;102:1651-1656.
69. Backhouse ME, Gnanasakthy A, Schulman KA, Akehurst R, Glick H. The development of standard economic datasets for use in the economic evaluation of medicines. *Drug Inf J*. 2000;34:1273-1291.
70. Kim J, Morris CB, Schulman KA. The role of the Food and Drug Administration in pharmacoeconomic evaluation during the drug development process. *Drug Inf J*. 2000;34:1207-1213.
71. Meehan KR, Areman EM, Ericson SG, Matias C, Seifeldin R, Schulman K. Mobilization, collection, and processing of autologous peripheral blood stem cells: development of a clinical process with associated costs. *J Hematother Stem Cell Res*. 2000;9:767-771.
72. Rathore SS, Gersh BJ, Berger PB, et al. Acute myocardial infarction complicated by heart block in the elderly: prevalence and outcomes. *Am Heart J*. 2001;141:47-54.

73. Berger AK, Breall JA, Gersh BJ, et al. Effect of diabetes mellitus and insulin use on survival after acute myocardial infarction in the elderly (The Cooperative Cardiovascular Project). *Am J Cardiol*. 2001;87:272-277.
74. Polsky D, Willke RJ, Scott K, Schulman KA, Glick HA. A comparison of scoring weights for the EuroQol© derived from patients and the general public. *Health Econ*. 2001;10:27-37.
75. Rathore SS, Weinfurt KP, Gersh BJ, Oetgen WJ, Schulman KA, Solomon AJ. Treatment of patients with myocardial infarction who present with a paced rhythm. *Ann Intern Med*. 2001;134:644-651.
76. Polsky D, Weinfurt KP, Kaplan B, Kim J, Fastenau J, Schulman KA. An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation. *Nephrol Dial Transplant*. 2001;16:1028-1033.
77. Weaver C, Schulman K, Buckner C. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. *Bone Marrow Transplant*. 2001;27(Suppl 2):S23-S29.
78. Rathore SS, Gersh BJ, Weinfurt KP, Oetgen WJ, Schulman KA, Solomon AJ. The role of reperfusion therapy in paced patients with acute myocardial infarction. *Am Heart J*. 2001;142:516-519.
79. DesHarnais Castel L, Bajwa K, Markle JP, Timbie JW, Zacker C, Schulman KA. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. *Support Care Cancer*. 2001;9:545-551.
80. Schulman KA, Yabroff KR, Kong J, et al. A claims data approach to defining an episode of care. *Pharmacoepidemiol Drug Saf*. 2001;10:417-427.
81. Weaver CH, Buckner CD, Curtis LH, et al. Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy. *Bone Marrow Transplant*. 2002;29:159-164.
82. Weinfurt KP, Trucco SM, Willke RJ, Schulman KA. Measuring agreement between patient and proxy responses to multidimensional health-related quality-of-life measures in clinical trials: an application of psychometric profile analysis. *J Clin Epidemiol*. 2002;55:608-618.
83. Gaskin D, Escarce JJ, Schulman K, Hadley J. The determinants of HMOs' contracting with hospitals for bypass surgery. *Health Serv Res*. 2002;37:963-984.
84. Schulman KA, Seils DM, Timbie JW, et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. *N Engl J Med*. 2002;347:1335-1341.
85. Polsky D, Keating NL, Weeks JC, Schulman KA. Patient choice of breast cancer treatment: impact on health state preferences. *Med Care*. 2002;40:1068-1079.
86. Onken JE, Friedman JY, Subramanian S, et al. Treatment patterns and costs associated with sessile colorectal lesions. *Am J Gastroenterol*. 2002;97:2896-2901.
87. Castel LD, Timbie JW, Sendersky V, Curtis LH, Feather KA, Schulman KA. Toward estimating the impact of changes in immigrants' insurance eligibility on hospital expenditures for uncompensated care. *BMC Health Serv Res*. 2003;3(1):1.
88. Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. *Am J Med*. 2003;114:135-141.
89. Law AW, Reed SD, Sundry JS, Schulman KA. Direct costs of allergic rhinitis in the united states: estimates from the 1996 Medical Expenditure Panel Survey. *J Allergy Clin Immunol*. 2003;111:296-300.
90. Schulman KA, Stadtmauer EA, Reed SD, et al. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem cell transplantation for metastatic breast cancer. *Bone Marrow Transplant*. 2003;31:205-210.
91. Polsky D, Mandelblatt JS, Weeks JC, et al. Economic evaluation of breast cancer treatment: considering the value of patient choice. *J Clin Oncol*. 2003;21:1139-1146.
92. Weinfurt KP, Castel LD, Sulmasy DP, et al. The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. *Cancer*. 2003;98:166-175.
93. Reed SD, Friedman JY, Gnanasakthy A, Schulman KA. Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial. *Int J Technol Assess Health Care*. 2003;19:396-406.
94. Meropol NJ, Weinfurt KP, Burnett CB, et al. Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. *J Clin Oncol*. 2003;21:2589-2596.
95. Shah BR, Reed SD, Francis J, Ridley DB, Schulman KA. The cost of inefficiency in US hospitals, 1985-1997. *J Health Care Finance*. 2003;30:1-9.
96. Sloan FA, Trogon JG, Curtis LH, Schulman KA. Does the ownership of the admitting hospital make a difference? Outcomes and process of care of Medicare beneficiaries admitted with acute myocardial infarction. *Med Care*. 2003;41:1193-1205.
97. Weinfurt KP, Sulmasy DP, Schulman KA, Meropol NJ. Patient expectations regarding benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. *Theor Med Bioeth*. 2003;24:329-344.

98. Bundorf MK, Escarce JJ, Stafford JA, Gaskin D, Jollis JG, Schulman KA. Impact of managed care on the treatment, costs, and outcomes of fee-for-service Medicare patients with acute myocardial infarction. *Health Serv Res.* 2004;39:131-152.
99. Sloan FA, Trogdon JG, Curtis LH, Schulman KA. The effect of dementia on outcomes and process of care for Medicare beneficiaries admitted with acute myocardial infarction. *J Am Geriatr Soc.* 2004;52:173-181.
100. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. *Med Care.* 2004;42:164-175.
101. Reed SD, Radeva JI, Glendenning GA, Saad F, Schulman KA. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. *J Urol.* 2004;171:1537-1542.
102. Liao L, Whellan DJ, Tabuchi K, Schulman KA. Differences in care-seeking behavior for acute chest pain in the United States and Japan. *Am Heart J.* 2004;147:630-635.
103. Curtis LH, Law AW, Anstrom AJ, Schulman KA. The insurance effect on prescription drug expenditures among the elderly: findings from the 1997 Medical Expenditure Panel Survey. *Med Care.* 2004;42:439-446.
104. Massie BM, Krol WF, Ammon SE, et al. The Warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): rationale, design, and baseline patient characteristics. *J Card Fail.* 2004;10:101-112.
105. Harpole LH, Oddone EZ, Stechuchak KM, Schulman KA. Technologies for receiving test results in primary care practices and the impact of managed care. *Journal of Clinical Outcomes Management.* 2004;11:216-222.
106. Rao SV, Schulman KA, Curtis LH, Gersh BJ, Jollis JG. Socioeconomic status and outcome following acute myocardial infarction in elderly patients. *Arch Intern Med.* 2004;164:1128-1133.
107. Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). *Am J Med.* 2004;148:122-128.
108. Patel MR, Meine TJ, Radeva J, et al. State-mandated continuing medical education and the use of proven therapies in patients with an acute myocardial infarction. *J Am Coll Cardiol.* 2004;44:192-198.
109. Curtis LH, Ostbye T, Sendersky V, et al. Inappropriate prescribing for elderly Americans in a large outpatient population. *Arch Intern Med.* 2004;164:1621-1625.
110. Kansagra SM, Curtis LH, Schulman KA. Regionalization of percutaneous transluminal coronary angioplasty and implications for patient travel distance. *JAMA.* 2004;292:1717-1723.
111. Hong TB, Oddone EZ, Weinfurt KP, Friedman JY, Schulman KA, Bosworth HB. The relationship between perceived barriers to healthcare and self-rated health. *Psychology, Health, and Medicine.* 2004;9:476-482.
112. Friedman JY, Reed SD, Weinfurt KP, Kahler KH, Walter EB, Schulman KA. Parents' reported preference scores for childhood atopic dermatitis disease states. *BMC Pediatr.* 2004;4:21.
113. Gaskin DJ, Weinfurt KP, Castel LD, et al. An exploration of relative health stock in advanced cancer patients. *Med Decis Making.* 2004;24:614-624.
114. Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA. Cost-effectiveness of imatinib versus interferon- α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. *Cancer.* 2004;101:2574-2583.
115. Anstrom KJ, Reed SD, Allen AS, Glendenning GA, Schulman KA. Long-term survival estimates for imatinib versus interferon- α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. *Cancer.* 2004;101:2584-2592.
116. Weinfurt KP, DePuy V, Castel LD, Sulmasy DP, Schulman KA, Meropol NJ. Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials. *Cancer.* 2005;103:140-147.
117. Radeva JI, Reed SD, Kalo Z, et al. Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation. *Clin Transplant.* 2005;19:122-129.
118. Reed SD, Radeva JI, Glendenning GA, Coleman RE, Schulman KA. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. *Am J Clin Oncol.* 2005;28:8-16.
119. Voils CI, Oddone EZ, Weinfurt KP, Friedman JY, Schulman KA, Bosworth HB. Who trusts healthcare institutions? Results from a community-based sample. *Ethn Dis.* 2005;15:97-103.
120. Reed SD, Friedman JY, Engemann JJ, et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible *Staphylococcus aureus* bacteremia. *Infect Control Hosp Epidemiol.* 2005;26:175-183.
121. Reed SD, Anstrom KJ, Bakhai A, et al. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. *Am Heart J.* 2005;149:434-443.
122. Eisenstein EL, Lemons PW III, Tardiff BE, Schulman KA, Jolly MK, Califf RM. Reducing the costs of phase III cardiovascular clinical trials. *Am Heart J.* 2005;149:482-488.

123. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. *Ann Oncol.* 2005;16:579-584.
124. Curtis LH, Masselink LE, Ostbye T, et al. Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. *Arch Pediatr Adolesc Med.* 2005;159:362-366.
125. Whellan DJ, Hasselblad V, Peterson E, O'Connor CM, Schulman KA. Meta-analysis and review of heart failure disease management randomized controlled clinical trials. *Am Heart J.* 2005;149:722-729.
126. Yancy WS Jr, Olsen MK, Curtis LH, Schulman KA, Cuffe MS, Oddone EZ. Variations in coronary procedure utilization depending on body mass index. *Arch Intern Med.* 2005;165:1381-1387.
127. Engemann JJ, Friedman JY, Reed SD, et al. Clinical outcomes and costs due to *Staphylococcus aureus* bacteremia among patients receiving long-term hemodialysis. *Infect Control Hosp Epidemiol.* 2005;26:534-539.
128. Ostbye T, Curtis LH, Masselink LE, et al. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. *Pharmacoepidemiol Drug Saf.* 2005;14:407-415.
129. Van Houtven CH, Voils CI, Oddone EZ, et al. Perceived discrimination and reported delay of pharmacy prescriptions and medical tests. *J Gen Intern Med.* 2005;20:578-583.
130. Chang J, Kauf TL, Mahajan S, et al. Impact of disease severity and gastrointestinal side effects on the health state preferences of patients with osteoarthritis. *Arthritis Rheum.* 2005;52:2366-2375.
131. Reed SD, Radeva JI, Weinfurt KP, et al. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). *Am Heart J.* 2005;150:323-329.
132. Friedman JY, Anstrom KJ, Weinfurt KP, et al. Perceived racial/ethnic bias in health care in Durham County, North Carolina: a comparison of community and national samples. *N C Med J.* 2005;66:267-275.
133. Reed SD, Radeva JI, Daniel DB, Fastenau JM, Williams D, Schulman KA. Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia. *Curr Med Res Opin.* 2005;21:1527-1533.
134. Meine TJ, Patel MR, DePuy V, et al. Evidence-based therapies and mortality in patients hospitalized in December with acute myocardial infarction. *Ann Intern Med.* 2005;143:481-485.
135. Rasiel EB, Weinfurt KP, Schulman KA. Can prospect theory explain risk-seeking behavior by terminally ill patients? *Med Decis Making.* 2005;25:609-613.
136. Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL. Trends in health care resource use for hepatitis C virus infection in the United States. *Hepatology.* 2005;42:1406-1413.
137. Chu VH, Crosslin DR, Friedman JY, et al. *Staphylococcus aureus* bacteremia in patients with prosthetic devices: costs and outcomes. *Am J Med.* 2005;118:1416.
138. Voils CI, Oddone EZ, Weinfurt KP, et al. Racial differences in health concern. *J Natl Med Assoc.* 2006;98:36-42.
139. Kauf TL, Velazquez EJ, Crosslin D, et al. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. *Am Heart J.* 2006;151:206-212.
140. Liao L, Jollis JG, Anstrom KJ, et al. Costs for heart failure with normal vs reduced ejection fraction. *Arch Intern Med.* 2006;166:112-118.
141. Weinfurt KP, Dinan MA, Allsbrook JS, et al. Policies of academic medical centers for disclosing conflicts of interest to potential research participants. *Acad Med.* 2006;81:113-118.
142. Sung JC, Curtis LH, Schulman KA, Albala DM. Geographic variations in the use of medical and surgical therapies for benign prostatic hyperplasia. *J Urol.* 2006;175:1023-1027.
143. Glickman SW, Rasiel EB, Hamilton CD, Kubataev A, Schulman KA. A portfolio model of drug development for tuberculosis. *Science.* 2006;311:1246-1247.
144. Ridley DB, Kramer JM, Tilson H, Grabowski HG, Schulman KA. Spending on postapproval drug safety. *Health Aff (Millwood).* 2006;25:429-436.
145. Inrig JK, Reed SD, Szczech LA, et al. Relationship between clinical outcomes and vascular access type among hemodialysis patients with *Staphylococcus aureus* bacteremia. *Clinical Journal of the American Society of Nephrology.* 2006;1:518-524.
146. Curtis LH, Stoddard J, Radeva JI, et al. Geographic variation in the prescription of Schedule II opioid analgesics among outpatients in the United States. *Health Serv Res.* 2006;41(3 Pt 1):837-855.
147. Reed SD, Radeva JI, Daniel DB, et al. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial. *Pharmacoeconomics.* 2006;24:475-479.
148. Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. *Ann Oncol.* 2006;17:986-989.
149. Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Albala DM, Moul JW. Prostate specific antigen testing in men older than 75 years in the United States. *J Urol.* 2006;176:511-514.
150. Reed SD, McMurray JJ, Velazquez EJ, et al. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. *Am Heart J.* 2006;152:500-508.

151. Torti FM Jr, Reed SD, Schulman KA. Analytic considerations in economic evaluations of multinational cardiovascular clinical trials. *Value Health*. 2006;9:281-291.
152. Reed SD, Califf RM, Schulman KA. How changes in drug safety regulations affect the way drug and biotech companies invest in innovation. *Health Aff (Millwood)*. 2006;25:1309-1317.
153. Dinan MA, Weinfurt KP, Friedman JY, et al. Comparison of conflict of interest policies and reported practices in academic medical centers in the United States. *Account Res*. 2006;13:325-342.
154. Curtis LH, Schulman KA. Overregulation of health care: musings on disruptive innovation theory. *Law Contemp Probl*. 2006;69(4):195-206.
155. Califf RM, Harrington RA, Madre LK, Peterson ED, Roth D, Schulman KA. Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics. *Health Aff (Millwood)*. 2007;26:62-74.
156. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. *JAMA*. 2007;297:159-168.
157. Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Dahm P, Moul JW. Relationship between body mass index and prostate cancer screening in the United States. *J Urol*. 2007;177:493-498.
158. Whellan DJ, Reed SD, Liao L, Gould SD, O'Connor CM, Schulman KA. Financial implications of a model heart failure disease management program for providers, hospital, healthcare systems, and payer perspectives. *Am J Cardiol*. 2007;99:256-260.
159. Whellan DJ, O'Connor DM, Lee KL, et al. Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION): design and rationale. *Am Heart J*. 2007;153:201-211.
160. Liao L, Anstrom KJ, Gottdiener JS, et al. Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study. *Am Heart J*. 2007;153:245-252.
161. Weinfurt KP, Allsbrook JS, Friedman JY, et al. Developing model language for disclosing financial interests to potential clinical research participants. *IRB*. 2007;29:1-5.
162. Kansagra SM, Curtis LH, Anstrom KJ, Schulman KA. Trends in operator and hospital procedure volume and outcomes for percutaneous transluminal coronary angioplasty, 1996 to 2001. *Am J Cardiol*. 2007;99:339-343.
163. Li JS, Eisenstein EL, Grabowski HG, et al. Economic return of clinical trials performed under the pediatric exclusivity program. *JAMA*. 2007;297:480-488.
164. Scales CD Jr, Curtis LH, Norris RD, et al. Changing gender prevalence of stone disease. *J Urol*. 2007;177:979-982.
165. Brown TT, Scheffler RM, Tom SE, Schulman KA. Does the market value racial and ethnic concordance in physician-patient relationships? *Health Serv Res*. 2007;42:706-726.
166. Turer AT, Mahaffey KW, Compton KL, Califf RM, Schulman KA. Publication or presentation of results from multicenter clinical trials: Evidence from an academic medical center. *Am Heart J*. 2007;153:674-680.
167. Glickman SW, Ou FS, DeLong ER, et al. Pay for performance, quality of care, and outcomes in acute myocardial infarction. *JAMA*. 2007;297:2373-2380.
168. Reed SD, Califf RM, Schulman KA. Is there a price to pay for short-term savings in the clinical development of new pharmaceutical products? *Drug Inf J*. 2007;41:491-499.
169. Grabowski HG, Ridley DB, Schulman KA. Entry and competition in generic biologics. *Managerial and Decision Economics*. 2007;28:439-451.
170. Friedman JY, Sugarman J, Dhillon JK, et al. Perspectives of clinical research coordinators on disclosing financial conflicts of interest to potential research participants. *Clin Trials*. 2007;4:272-278.
171. DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. *Support Care Cancer*. 2007;15:869-876.
172. Curtis LH, Hammill BG, Bethel MA, Anstrom KJ, Gottdiener JS, Schulman KA. Costs of metabolic syndrome in elderly individuals: findings from the Cardiovascular Health Study. *Diabetes Care*. 2007;30:2553-2558.
173. Curtis LH, Al-Khatib SM, Shea AM, Hammill BG, Hernandez AF, Schulman KA. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. *JAMA*. 2007;298:1517-1524.
174. Shah BR, Glickman SW, Liang L, et al. The impact of for-profit hospital status on the care and outcomes of patients with non-ST-segment elevation myocardial infarction: results from the CRUSADE initiative. *J Am Coll Cardiol*. 2007;50:1462-1468.
175. Friedman JY, Curtis LH, Hammill BG, et al. The Medicare Modernization Act and reimbursement for outpatient chemotherapy: Do patients perceive changes in access to care? *Cancer*. 2007;110:2304-2312.
176. Glickman SW, Baggett KA, Krubert CG, Peterson ED, Schulman KA. Promoting quality: the health care organization from a management perspective. *Int J Qual Health Care*. 2007;19:341-348.
177. Glickman SW, Boulding W, Staelin R, et al. A framework for quality improvement: an analysis of factors responsible for improvement at hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress

Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality improvement initiative. *Am Heart J*. 2007;154:1206-1220.

178. Shea AM, Reed SD, Curtis LH, Alexander MJ, Villani JJ, Schulman KA. Characteristics of nontraumatic subarachnoid hemorrhage in the United States in 2003. *Neurosurgery*. 2007;61:1131-1138.
179. Williams JE, Anstrom KJ, Friedman JY, Schulman KA. Racial/ethnic variation in perceptions of medical information sources in Durham County, North Carolina. *N C Med J*. 2007;68:391-398.
180. Curtis LH, Hammill BG, Bethel MA, et al. Pancreatic beta-cell function as a predictor of cardiovascular outcomes and costs: findings from the Cardiovascular Health Study. *Curr Med Res Opin*. 2008;24:41-50.
181. Reed SD, Shea AM, Schulman KA. Economic implications of potential changes to regulatory and reimbursement policies for medical devices. *J Gen Intern Med*. 2008;23(Suppl 1):50-56.
182. Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. *Arch Intern Med*. 2008;168:418-424.
183. Konstance RP, Eisenstein EL, Anstrom KJ, et al. Outcomes of second revascularization procedures after stent implantation. *J Med Syst*. 2008;32:177-186.
184. Hammill BG, Curtis LH, Bennett-Guerrero E, et al. Impact of heart failure on patients undergoing major noncardiac surgery. *Anesthesiology*. 2008;108:559-567.
185. Shea AM, Hammill BG, Curtis LH, Szczech LA, Schulman KA. Medical costs of abnormal serum sodium levels. *J Am Soc Nephrol*. 2008;19:764-770.
186. Glickman SW, Schulman KA, Peterson ED, Hocker MB, Cairns CB. Evidence-based perspectives on pay for performance and quality of patient care and outcomes in emergency medicine. *Ann Emerg Med*. 2008;51:622-631.
187. Reed SD, Anstrom KJ, Li Y, Schulman KA. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. *Pharmacoeconomics*. 2008;26:435-446.
188. Weinfurt KP, Seils DM, Tzeng JP, Lin L, Schulman KA, Califf RM. Consistency of financial interest disclosures in the biomedical literature: the case of coronary stents. *PLoS ONE*. 2008;3:e2128.
189. Fleisher L, Buzaglo J, Collins M, et al. Using health communication best practices to develop a web-based provider-patient communication aid: the CONNECT study. *Patient Educ Couns*. 2008;71:378-387.
190. Glickman SW, Anstrom KJ, Lin L, et al. Challenges in enrollment of minority, pediatric, and geriatric patients in emergency and acute care clinical research. *Ann Emerg Med*. 2008;51:775-780.
191. Shea AM, Curtis LH, Szczech LA, Schulman KA. Sensitivity of International Classification of Diseases codes for hyponatremia among commercially insured outpatients in the United States. *BMC Nephrol*. 2008;9:5.
192. Shea AM, Curtis LH, Hammill BG, DiMartino LD, Abernethy AP, Schulman KA. Association between the Medicare Modernization Act of 2003 and patient wait times and travel distance for chemotherapy. *JAMA*. 2008;300:189-196.
193. Bearely S, Mruthyunjaya P, Tzeng JP, et al. Identification of patients with diabetic macular edema from claims data: a validation study. *Arch Ophthalmol*. 2008;126:986-989.
194. Kyle MK, Allsbrook JS, Schulman KA. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union. *Health Serv Res*. 2008;43:1308-1324.
195. Weinfurt KP, Seils DM, Tzeng JP, et al. Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. *Med Decis Making*. 2008;28:575-581.
196. Reed SD, Anstrom KJ, Seils DM, Califf RM, Schulman KA. Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs. *Health Aff (Millwood)*. 2008;27:w360-w730.
197. Takahashi T, Reed SD, Schulman KA. Cost-effectiveness of the oral adsorbent AST-120 vs placebo for chronic kidney disease. *Nephrology (Carlton)*. 2008;13:419-427.
198. Flynn KE, Weinfurt KP, Seils DM, et al. Decisional conflict among patients who accept or decline participation in phase I oncology studies. *J Empir Res Hum Res Ethics*. 2008;3:69-77.
199. Scales CD Jr, Antonelli J, Curtis LH, Schulman KA, Moul JW. Prostate-specific antigen screening among young men in the United States. *Cancer*. 2008;113:1315-1323.
200. Richman BD, Udayakumar K, Mitchell W, Schulman KA. Lessons from India in organizational innovation: a tale of two heart hospitals. *Health Aff (Millwood)*. 2008;27:1260-1270.
201. Weinfurt KP, Hall MA, Friedman JY, et al. Effects of disclosing financial interests on participation in medical research: a randomized vignette trial. *Am Heart J*. 2008;156:689-697.
202. Dev AT, Kauf TL, Zekry A, et al. Factors influencing the participation of gastroenterologists and hepatologists in clinical research. *BMC Health Serv Res*. 2008;8:208.
203. Al-Khatib SM, Greiner MA, Peterson ED, Hernandez AF, Schulman KA, Curtis LH. Patient and implanting physician factors associated with mortality and complications following implantable cardioverter-defibrillator implantation, 2002-2005. *Circ Arrhythm Electrophysiol*. 2008;1:240-249.
204. Califf RM, Rasiel EB, Schulman KA. Consideration of net present value in policy making regarding diagnostic and therapeutic technologies. *Am Heart J*. 2008;156:879-885.

205. Chatterji AK, Fabrizio KR, Mitchell W, Schulman KA. Physician-industry cooperation in the medical device industry. *Health Aff (Millwood)*. 2008;27:1532-1543.
206. Flynn KE, Dombeck CB, DeWitt EM, Schulman KA, Weinfurt KP. Using item banks to construct measures of patient reported outcomes in clinical trials: investigator perceptions. *Clin Trials*. 2008;5:575-586.
207. Hernandez AF, Shea AM, Milano CA, et al. Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries. *JAMA*. 2008;300:2398-2406.
208. Ackerly DC, Valverde AM, Diener LW, Dossary KL, Schulman KA. Fueling innovation in medical devices (and beyond): venture capital in health care. *Health Aff (Millwood)*. 2008;28:w68-w75.
209. Curtis LH, Greiner MA, Hammill BG, et al. Early and long-term outcomes of heart failure in elderly persons, 2001-2005. *Arch Intern Med*. 2008;168:2481-2488.
210. Shea AM, Curtis LH, Hammill BG, et al. Resource use and costs associated with diabetic macular edema in elderly persons. *Arch Ophthalmol*. 2008;126:1748-1754.
211. DiMartino LD, Curtis LH, Williams RL, Abernethy DR, Schulman KA. Using Medicare administrative data to conduct postmarketing surveillance on follow-on biologics: issues and opportunities. *Food Drug Law J*. 2008;63:891-900.
212. Zafar SY, Alexander SC, Weinfurt KP, Schulman KA, Abernethy AP. Decision making and quality of life in the treatment of cancer: a review. *Support Care Cancer*. 2009;17:117-127.
213. Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry. *J Am Coll Cardiol*. 2009;53:184-192.
214. Hall MA, Weinfurt KP, Lawlor JS, Friedman JY, Schulman KA, Sugarman J. Community hospital oversight of clinical investigators' financial relationships. *IRB*. 2009;31:7-13.
215. Li Y, Friedman JY, O'Neal BF, et al. Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients. *Clin J Am Soc Nephrol*. 2009;4:428-434.
216. Massie BM, Collins JF, Ammon SE, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. *Circulation*. 2009;119(12):1616-1624.
217. O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: the HF-ACTION randomized controlled trial. *JAMA*. 2009;301(14):1439-1450.
218. Flynn KE, Piña IL, Whellan DJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA*. 2009;301(14):1451-1459.
219. Reed SD, Li Y, Anstrom KJ, Schulman KA. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. *J Clin Oncol*. 2009;27(13):2185-2191.
220. Wideroff L, Phillips KA, Randhawa G, et al. A health services research agenda for cellular, molecular and genomic technologies in cancer care. *Public Health Genomics*. 2009;12(4):233-244.
221. Glickman SW, McHutchison JG, Peterson ED, et al. Ethical and scientific implications of the globalization of clinical research. *N Engl J Med*. 2009;360:816-823.
222. Hammill BG, Hernandez AF, Peterson ED, Fonarow GC, Schulman KA, Curtis LH. Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. *Am Heart J*. 2009;157(6):995-1000.
223. DiMartino LD, Hammill BG, Curtis LH, et al. External validity of the Cardiovascular Health Study: a comparison with the Medicare population. *Med Care*. 2009;47(8):916-923.
224. Schulman KA, Vidal AV, Ackerly DC. Personalized medicine and disruptive innovation: implications for technology assessment. *Genet Med*. 2009;11(8):577-581.
225. Weinfurt KP, Hall MA, King NM, Friedman JY, Schulman KA, Sugarman J. Disclosing financial relationships to participants in clinical research. *N Engl J Med*. 2009;361(9):916-921.
226. Flynn KE, Lin L, Ellis SJ, et al. Relationships between patient-reported outcome measures and clinical measures in outpatients with heart failure. *Am Heart J*. 2009;158(4 Suppl 1):S64-S71.
227. Glickman SW, Boulding W, Roos JM, Staelin R, Peterson ED, Schulman KA. Alternative pay-for-performance scoring methods: implications for quality improvement and patient outcomes. *Med Care*. 2009;47(10):1062-1068.
228. DeWitt EM, Lin L, Glick HA, Anstrom KJ, Schulman KA, Reed SD. Pattern and predictors of biologics initiation in rheumatoid arthritis: an ARAMIS cohort study. *Clin Ther*. 2009;31(8):1871-1880.
229. Dinan MA, Chou CH, Hammill BG, et al. Outcomes of inpatients with and without sickle cell disease after high-volume surgical procedures. *Am J Hematol*. 2009;84(11):703-709.
230. Patterson ME, Grant WC, Glickman SW, et al. Resource use and the costs of treatment with anticoagulation and antiplatelet agents: results of the WATCH trial economic evaluation. *J Card Fail*. 2009;15(10):819-827.
231. Fekrat S, Shea AM, Hammill BG, et al. Resource use and costs of branch and central retinal vein occlusion in the elderly. *Curr Med Res Opin*. 2010;26(1):223-230.
232. Hammill BG, Curtis LH, Schulman KA, Whellan DJ. Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries. *Circulation*. 2010;121(1):63-70.

233. Hernandez AF, Fonarow GC, Hammill BG, et al. Clinical effectiveness of implantable cardioverter-defibrillators among Medicare beneficiaries with heart failure. *Circ Heart Fail*. 2010;3(1):7-13.
234. Whellan DJ, Greiner MA, Schulman KA, Curtis LH. Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004. *Circ Cardiovasc Qual Outcomes*. 2010;3(1):33-40.
235. Glickman SW, Krubert C, Koppenhaver J, Glickman LT, Schulman KA, Cairns CB. Increased rate of central venous catheterization procedures in community EDs. *Am J Emerg Med*. 2010;28(2):208-212.
236. Fortune-Greeley AK, Hardy NC, Lin L, et al. Patient reactions to confidentiality, liability, and financial aspects of informed consent in cardiology research. *Circ Cardiovasc Qual Outcomes*. 2010;3(2):151-158.
237. Glickman SW, Boulding W, Manary M, et al. Patient satisfaction and its relationship with clinical quality and inpatient mortality in acute myocardial infarction. *Circ Cardiovasc Qual Outcomes*. 2010;3(2):188-195.
238. Petersen JL, Barron JJ, Hammill BG, et al. Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database. *Am Heart J*. 2010;159(3):462-470.e1.
239. Hernandez AF, Hammill BG, Peterson ED, et al. Relationships between emerging measures of heart failure processes of care and clinical outcomes. *Am Heart J*. 2010;159(3):406-413.
240. Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. *Diabetes Technol Ther*. 2010;12(4):249-255.
241. Ackerly DC, Glickman SW, Schulman KA. Economic content in medical journal advertisements for medical devices and prescription drugs. *Pharmacoeconomics*. 2010;28(5):429-438.
242. Weinfurt KP, Hall MA, Hardy NC, Friedman JY, Schulman KA, Sugarman J. Oversight of financial conflicts of interest in commercially sponsored research in academic and nonacademic settings. *J Gen Intern Med*. 2010;25(5):460-464.
243. Dinan MA, Curtis LH, Hammill BG, et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. *JAMA*. 2010;303(16):1625-1631.
244. Vaughn BT, DeVrieze SR, Reed SD, Schulman KA. Can we close the income and wealth gap between specialists and primary care physicians? *Health Aff (Millwood)*. 2010;29(5):933-940.
245. Reed SD, Whellan DJ, Li Y et al. Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure. *Circ Cardiovasc Qual Outcomes*. 2010;3(4):374-381.
246. Chou CH, Reed SD, Allsbrook JS, Steele JL, Schulman KA, Alexander MJ. Costs of vasospasm in patients with aneurysmal subarachnoid hemorrhage. *Neurosurgery*. 2010;67(2):345-352.
247. Patel MR, Greiner MA, Dimartino LD, et al. Geographic variation in carotid revascularization among Medicare beneficiaries, 2003-2006. *Arch Intern Med*. 2010;170(14):1218-1225.
248. Patterson ME, Hernandez AF, Hammill BG, et al. Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. *Med Care*. 2010;48(3):210-216.
249. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. *Arch Ophthalmol*. 2010;128(10):1273-1279.
250. Curtis LH, Greiner MA, Patel MR, Duncan PW, Schulman KA, Matchar DB. Geographic variation and trends in carotid imaging among Medicare beneficiaries, 2001 to 2006. *Circ Cardiovasc Qual Outcomes*. 2010;3(6):599-606.
251. Nagler A, Andolsek K, Dossary K, Schlueter J, Schulman K. Addressing the systems-based practice requirement with health policy content and educational technology. *Med Teach*. 2010;32(12):e559-e565.
252. Curtis LH, Greiner MA, Shea AM, et al. Assessment of left ventricular function in elderly Medicare beneficiaries with newly diagnosed heart failure. *Circ Cardiovasc Qual Outcomes*. 2011;4(1):85-91.
253. Reed SD, Scales CD, Jr., Stewart SB, et al. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. *J Urol*. 2011;185(3):841-847.
254. Boulding W, Glickman SW, Manary MP, Schulman KA, Staelin R. Relationship between patient satisfaction with inpatient care and hospital readmission within 30 days. *Am J Manag Care*. 2011;17(1):41-48.
255. Unroe KT, Greiner MA, Hernandez AF, et al. Resource use in the last 6 months of life among Medicare beneficiaries with heart failure, 2000-2007. *Arch Intern Med*. 2011;171(3):196-203.
256. Glickman SW, Nduvizi A, Weinfurt KP, et al. The case for research justice: inclusion of patients with limited English proficiency in clinical research. *Acad Med*. 2011;86(3):389-393.
257. Dinan MA, Compton KL, Dhillon JK, et al. Use of patient-reported outcomes in randomized, double-blind, placebo-controlled clinical trials. *Med Care*. 2011;49(4):415-419.
258. Wiener JS, Antonelli J, Shea AM, et al. Bladder augmentation versus urinary diversion in patients with spina bifida in the United States. *J Urol*. 1999;186(1):161-165.
259. Segall N, Saville JG, L'Engle P, et al. Usability evaluation of a personal health record. *AMIA Ann Symp Proc*. 2011;2011:1233-1242.

260. Reed SD, Li Y, Kamble S, et al. Introduction of the TEAM-HF costing tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions. *Circ Cardiovasc Qual Outcomes*. 2012;5(1):113-119.
261. Greiner MA, Hammill BG, Fonarow GC, et al. Predicting high costs among Medicare beneficiaries with heart failure. *Am J Cardiol*. 2012;109(5):705-711.
262. Glickman SW, Galhenage S, McNair L, et al. The potential influence of Internet-based social networking on the conduct of clinical research studies. *J Empir Res Hum Res Ethics*. 2012;7(1):71-80.
263. Dinan MA, Robinson TJ, Zagar TM, et al. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. *Int J Radiat Oncol Biol Phys*. 2012;82(5):e781-e786.
264. DeWitt EM, Grussemeyer CA, Friedman JY, Dinan MA, Schulman KA, Reed SD. Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial. *Value Health*. 2012;15(2):277-283.
265. Baras AI, Baras AS, Schulman KA. Drug development risk and the cost of capital. *Nat Rev Drug Discov*. 2012;11(5):347-348.
266. Curtis LH, Hammill BG, Qualls LG, et al. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 Medicare beneficiaries. *Am J Ophthalmol*. 2012;153(6):1116-1124.e1.
267. Dinan MA, Curtis LH, Carpenter WR, et al. Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among Medicare beneficiaries with non-small-cell lung cancer, 1998-2003. *J Clin Oncol*. 2012;30(22):2725-2730.
268. Kamble S, Schulman KA, Reed SD. Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States. *Value Health*. 2012;15(5):632-638.
269. Gellad ZF, Muir AJ, McHutchison JG, et al. Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. *Value Health*. 2012;15(6):876-886.
270. Reed SD, Li Y, Ellis SJ, et al. Associations between hemoglobin level, resource use, and medical costs in patients with heart failure: findings from HF-ACTION. *J Card Fail*. 2012;18(10):784-791.
271. Jimoh LY, Pate MA, Lin L, Schulman KA. A model for the adoption of ICT by health workers in Africa. *Int J Med Inform*. 2012;81(11):773-781.
272. Reed SD, Li Y, Dunlap ME, et al. In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). *Am J Cardiol*. 2012;110(8):1150-1155.
273. Valverde AM, Reed SD, Schulman KA. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases. *Health Aff (Millwood)*. 2012;31(11):2528-2535.
274. Peterson AC, Curtis LH, Shea AM, et al. Urinary diversion in patients with spinal cord injury in the United States. *Urology*. 2012;80(6):1247-1251.
275. DeWitt EM, Li Y, Curtis JR, et al. Comparative effectiveness of non-biologic versus biologic DMARDs for rheumatoid arthritis: methodological considerations. *J Rheumatol*. 2013;40(2):127-136.
276. Kamble S, Weinfurt KP, Perry BM, Schulman KA, Reed SD. Patient time and indirect costs associated with sensor-augmented insulin pump therapy in type 1 diabetes: results from a randomized trial. *Med Decis Making*. 2013;33(2):215-224.
277. Meropol NJ, Eggleston BL, Buzaglo JS, et al. A Web-based communication aid for patients with cancer: the CONNECT study. *Cancer*. 2013;119(7):1437-1445.
278. Reed SD, Dinan MA, Schulman KA, Lyman GH. Cost-effectiveness of the 21-gene Recurrence Score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. *Genet Med*. 2013;15(3):203-211.
279. Qualls LG, Hammill BG, Wang F, et al. Costs of newly diagnosed neovascular age-related macular degeneration among Medicare beneficiaries, 2004-2008. *Retina*. 2013;33(4):854-861.
280. Li Y, Neilson MP, Whellan DJ, Schulman KA, Levy WC, Reed SD. Associations between Seattle Heart Failure Model scores and health utilities: findings from HF-ACTION. *J Card Fail*. 2013;19(5):311-316.
281. Dinan MA, Curtis LH, Carpenter WR, et al. Variation in the use of positron emission tomography among Medicare beneficiaries with non-small-cell lung cancer, 1998-2005. *Radiology*. 2013;267(3):807-817.
282. Hirsch BR, Califf RM, Cheng SK, et al. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. *JAMA Intern Med*. 2013;173(11):972-979.
283. Reed SD, Kaul P, Li Y, et al. Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: findings from ASCEND-HF. *J Card Fail*. 2013;19(9):611-620.
284. Eapen ZJ, Hammill BG, Setoguchi S, et al. Who enrolls in the Medicare Part D prescription drug benefit program? Medication use among patients with heart failure. *J Am Heart Assoc*. 2013;2(5):e000242.
285. Pina IL, Lin L, Weinfurt KP, et al. Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial). *Am J Cardiol*. 2013;112(7):971-976.

286. Lewis EF, Li Y, Pfeffer MA, et al. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (Valsartan in Acute Myocardial Infarction). *JACC Heart Fail*. 2014;2(2):159-165.
287. Dinan MA, Curtis LH, Carpenter WR, et al. Redistribution of health care costs after the adoption of positron emission tomography among Medicare beneficiaries with non-small-cell lung cancer, 1998-2005. *J Thorac Oncol*. 2014;9(4):512-518.
288. Kalman NS, Hammill BG, Murray RB, Schulman KA. Removing a constraint on hospital utilization: a natural experiment in Maryland. *Am J Manag Care*. 2014;20(6):e191-e199.
289. Wen J, Schulman KA. Can team-based care improve patient satisfaction? A systematic review of randomized controlled trials. *PLoS One*. 2014;9(7):e100603.
290. Li Y, Levy WC, Neilson MP, et al. Associations between seattle heart failure model scores and medical resource use and costs: findings from HF-ACTION. *J Card Fail*. 2014;20(8):541-547.
291. Sama PR, Eapen ZJ, Weinfurt KP, Shah BR, Schulman KA. An evaluation of mobile health application tools. *JMIR Mhealth Uhealth*. 2014;2(2):e19.
292. Hirsch BR, Balu S, Schulman KA. The impact of specialty pharmaceuticals as drivers of health care costs. *Health Aff (Millwood)*. 2014;33(10):1714-1720.
293. Dardas T, Levy W, Reed S, et al. Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with heart failure. *J Heart Lung Transplant*. 2015;34(8):1017-1023.
294. Mühlbacher AC, Bethge S, Reed SD, Schulman KA. Patient preferences for features of health care delivery systems: a discrete choice experiment. *Health Serv Res*. 2015 Aug 10. doi: 10.1111/1475-6773.12345. [Epub ahead of print]
295. Reed SD, Neilson MP, Gardner M, Li Y, Briggs AH, Polsky DE, Graham FL, Bowers MT, Paul SC, Granger BB, Schulman KA, Whellan DJ, Riegel B, Levy WC. Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. *Am Heart J*. 2015 Nov;170(5):951-60. Epub 2015 Aug 20.
296. Glickman SW, Mehrotra A, Shea CM, Mayer C, Strickler J, Pabers S, Larson J, Goldstein B, Mandelkehr L, Cairns CB, Pines JM, Schulman KA. A Patient Reported Approach to Identify Medical Errors and Improve Patient Safety in the Emergency Department. *J Patient Saf*. 2016 Nov 2. [Epub ahead of print]
297. Levy WC, Li Y, Reed SD, Zile MR, Shadman R, Dardas T, Whellan DJ, Schulman KA, Ellis SJ, Neilson M, O'Connor CM; HF ACTION Investigators. Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? *JACC Clin Electrophysiol*. 2017 Mar;3(3):291-298.
298. Maniya OZ, Mather RC 3rd, Attarian DE, et al. Modeling the potential economic impact of the Medicare Comprehensive Care for Joint Replacement episode-based payment model. *J Arthroplasty*. 2017 Jun 8. [Epub ahead of print]
299. Hardy M, Cho A, Stavig A, Bratcher M, Dillard J, Greenblatt L, Schulman K. Understanding Frequent Emergency Department Use Among Primary Care Patients. *Popul Health Manag*. 2017. PMID: 28609191
300. Sendak M, Balu S, Schulman KA. "Barriers to Achieving Economies of Scale in Analysis of EHR Data: A Cautionary Tale. *Appl Clin Infor* 2017; 8: 826-831
301. Clough J, Dinan M, Schulman KA. Trends in Hospital-Physician Integration in Medical Oncology. *Am J Manag Care*. 2017 Oct;23(10):624-627.

REVIEW ARTICLES AND COMMENTARIES:

1. Schulman KA, Lynn LA. A primer on cost-effectiveness studies. *Drug Benefit Topics*. 1990;2:13-17.
2. Schulman KA. Basics of health insurance reimbursement. *Hosp Physician*. 1990;26:23-27.
3. Glick H, Kinosian B, Schulman K. Decision analytic modeling: some uses in the evaluation of new pharmaceuticals. *Drug Inf J*. 1994;28:691-707.
4. Schulman KA, Glick HA, Yabroff KR, Eisenberg JM. Introduction to clinical economics: assessment of cancer therapies. *J Natl Cancer Inst Monogr*. 1995;(19):1-9.
5. Schulman KA, Rubenstein LE, Chesley FD, Eisenberg JM. The roles of race and socioeconomic factors in health services research. *Health Serv Res*. 1995;30(1 Pt 2):179-195.
6. Schulman KA, Yabroff KR. Measuring the cost-effectiveness of cancer care. *Oncology*. 1995;9:523-533.
7. Yabroff KR, Linas BP, Schulman K. Evaluation of quality of life for diverse patient populations. *Breast Cancer Res Treat*. 1996;40:87-104.
8. Schulman KA, Rubenstein LE, Glick HA, Eisenberg JM. Relationships between sponsors and investigators in pharmaco-economic and clinical research. *Pharmacoeconomics*. 1995;7:206-220.
9. Schulman KA. Economics of bone marrow transplantation. *J Clin Oncol*. 1996;14:1409-1410.

10. Schulman KA, Rubenstein LE, Abernethy DR, Seils DM, Sulmasy DP. The effect of pharmaceutical benefits managers: is it being evaluated? *Ann Intern Med.* 1996;124:906-913.
11. Schulman KA, Llana T, Yabroff KR. Economic assessment within the clinical development program. *Med Care.* 1996;34(12 Suppl):DS89-DS95.
12. Schulman KA. Understanding the economic savings and costs of periodic mammographic screening in the workplace. *Oncology.* 1996;10:285-284.
13. Tom E, Schulman KA. Mathematical models in decision analysis. *Infect Control Hosp Epidemiol.* 1997;18:65-73.
14. Schulman KA, Linas BP. Pharmacoeconomics: state of the art in 1997. *Annu Rev Public Health.* 1997;18:529-548.
15. Schulman KA, Johnson AE, Rathore SS. The use of satisfaction measures in oncology. *ASCO Education Book.* 1997;Spring:337-341.
16. Schulman KA, Boyko WL, Jr. Evaluating cancer costs in NCI trials. *Cancer Treat Res.* 1998;97:37-52.
17. Schulman KA, Mark DB, Califf RM. Outcomes and costs within a disease management program for advanced congestive heart failure. *Am Heart J.* 1998;135(6 Pt 2 Su):S285-S292.
18. Schulman KA. Beyond survival: economic analyses of chemotherapy in advanced, inoperable, non small cell lung cancer. *Oncology.* 2000;12:219-223.
19. Schulman KA, Ohishi A, Park J, Glick HA, Eisenberg JM. Clinical economics in clinical trials: the measurement of cost and outcomes in the assessment of clinical services through clinical trials. *Keio J Med.* 1999;48:1-11.
20. Sheifer SE, Schulman KA. Racial differences in the use of invasive cardiac procedures: a continuous quality improvement approach. *Am Heart J.* 1999;138(3 Pt 1):396-399.
21. Winchester JF, Levine B, Collmann J, et al. Telemedicine: future promise for dialysis management. *Semin Dial.* 1999;12(Suppl 1):S101-S103.
22. Sheifer SE, Escarce JJ, Schulman KA. Race and sex differences in the management of coronary artery disease. *Am Heart J.* 2000;139:848-857.
23. Schulman KA, Kim JJ. Medical errors: how the US government is addressing the problem. *Curr Control Trials Cardiovasc Med.* 2000;1:35-37.
24. Einbinder LC, Schulman KA. The effect of race on the referral process for invasive cardiac procedures. *Med Care Res Rev.* 2000;57 Suppl 1:162-180.
25. Seils DM, Friedman JY, Schulman KA. Sex differences in the referral process for invasive cardiac procedures. *J Am Med Womens Assoc.* 2001;56:151-154.
26. Schulman KA. Understanding attitudes toward clinical research. *J Ambul Care Manage.* 2003;26:88-90.
27. Schulman KA, Seils DM. Outcomes research in oncology: improving patients' experiences with cancer treatment. *Clin Ther.* 2003;25:665-670.
28. Wang SS, Mendelson DN, Schulman KA, Mark DB. Exploring options for improving healthcare. *Am Heart J.* 2004;147:23-30.
29. Schulman KA. Commentary: Garson's "Physicians, coverage, quality, and cost: the intertwined caduceus." *J Am Coll Cardiol.* 2004;43:6-7.
30. Torti FM Jr, Gwyther LP, Reed SD, Friedman JY, Schulman KA. A multinational review of recent trends and reports in dementia caregiver burden. *Alzheimer Dis Assoc Disord.* 2004;18:99-109.
31. Ridley DB, Schulman KA. Differential pricing of pharmaceuticals in the Internet age. *J Ambul Care Manage.* 2004;27:210-214.
32. Seils DM, Schulman KA. Perceptions of racial and ethnic differences in access to healthcare. *N C Med J.* 2004;65:350-352.
33. Schulman KA. Commentary: The unknown benefit of complementary and alternative medicine. *J Altern Complement Med.* 2004;10:911.
34. Schulman KA. Annotated bibliography. *Breast Diseases: A Year Book Quarterly.* 2004;15:468.
35. Meropol NJ, Desmond-Hellman S, Tunis S, Schulman KA. Can society afford state-of-the-art cancer treatment? *ASCO Educational Book.* 2005;:473-480.
36. Ginsburg GS, Konstance RP, Allsbrook JS, Schulman KA. Implications of pharmacogenomics for drug development and clinical practice. *Arch Intern Med.* 2005;165:2331-2336.
37. Meropol NJ, Schulman KA. Perspectives on the cost of cancer care. *J Clin Oncol.* 2007;25:169-170.
38. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. *J Clin Oncol.* 2007;25:180-186.
39. Hall MA, Schulman KA. Ownership of medical information. *JAMA.* 2009;301(12):1282-1284.
40. Reed SD, Schulman KA. Cost-utility of sequential adjuvant trastuzumab for HER2/neu-positive breast cancer. *Value Health.* 2009;12(5):637-640.
41. Glickman SW, Cairns CB, Schulman KA. Ethical and scientific implications of the globalization of clinical research. *N Engl J Med.* 2009;360(26):2793.
42. Yancy WS, Jr., Maciejewski ML, Schulman KA. Animal, vegetable, or ... clinical trial? *Ann Intern Med.* 2010;153(5):337-339.

43. Hall MA, Friedman JY, King NM, Weinfurt KP, Schulman KA, Sugarman J. Per capita payments in clinical trials: reasonable costs versus bounty hunting. *Acad Med*. 2010;85(10):1554-1556.
44. Ahmad A, Schulman K. Moving forward with clinical IT on multiple fronts: an interview with Asif Ahmad and Kevin Schulman, M.D., Duke University Health System/Duke University. *Healthc Inform*. 2010;27(10):45-47.
45. Schulman KA, Tunis SR. A policy approach to the development of molecular diagnostic tests. *Nat Biotechnol*. 2010;28(11):1157-1159.
46. Richman BD, Havighurst CC, Berenson RA, Schulman KA. A cautious path forward on accountable care organizations. *JAMA*. 2011;305(6):602-603.
47. Sampson JH, Kaminski TJ, Schulman KA. Our failure to advance new treatments for glioma to market. *J Neurosurg*. 2011;115(2):245-247.
48. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. *Lancet Oncol*. 2011;12(10):933-980.
49. Reed SD, Eapen ZJ, Schulman KA. End point selection in acute decompensated heart failure clinical trials: economic end points. *Heart Fail Clin*. 2011;7(4):529-37.
50. Ackerly DC, Sangvai D, Udayakumar K, et al. Training the next generation of physician-executives: an innovative residency pathway in management and leadership. *Acad Med*. 2011;86(5):75-79.
51. Patel UD, Schulman KA. Can we begin with the end in mind? End-of-life care preferences before chronic dialysis. *Arch Intern Med*. 2012;172(8):663-664.
52. Richman BD, Hall MA, Schulman KA. Overbilling and informed financial consent--a contractual solution. *N Engl J Med*. 2012;367(5):396-397.
53. Schulman KA. Creation of the Business School Alliance for Health Management. *Health Management, Policy and Innovation*. 2012;1(1):42-43.
54. Hirsch BR, Schulman KA. The economics of new drugs: Can we afford to make progress in a common disease? *Am Soc Clin Oncol Educ Book*. 2013:e126-e130.
55. Richman BD, Mitchell W, Schulman KA. Organizational innovation in health care. *Health Management, Policy and Innovation*. 2013;1(3):36-44.
56. Dolor RJ, Schulman KA. Financial incentives in primary care practice: the struggle to achieve population health goals. *JAMA*. 2013;310(10):1031-1032.
57. Glickman SW, Schulman KA. The mis-measure of physician performance. *Am J Manag Care*. 2013;19(10):782-785.
58. Huesch MD, Schulman KA, Douglas PS. Could accountable care organizations stifle physician learning and innovation? *Health Management, Policy and Innovation*. 2014;2(1):18-28.
59. Shah BR, Narayan M, Seth A, Schulman KA. Health City Cayman Islands and the globalization of health services delivery. *Am Heart J*. 2014;167(5):770-774.
60. Schulman KA, Richman BD, Herzlinger RE. Shifting toward defined contributions—predicting the effects. *N Engl J Med*. 2014;370(26):2462-2465.
61. Scales CD Jr, Schulman KA. Triggering management for quality improvement. *Health Serv Res*. 2014;49(5):1401-1406.
62. Schulman KA. Review: in adult outpatients, nurse-managed protocols improve hemoglobin A1c levels and blood pressure. *Ann Intern Med*. 2014;161(12):JC6.
63. Herzlinger R, Ramaswamy VK, Schulman KA. Bridging health care's innovation-education gap. *Harv Bus Rev*. 2014 Nov 11. <https://hbr.org/2014/11/bridging-health-cares-innovation-education-gap>.
64. Dinan MA, Schulman KA. Exploring variation in care: alternative conceptual models. *Ann Intern Med*. 2014;161(11):835-836.
65. Richman BD, Schulman KA. The Partners HealthCare Settlement and the Future of Health Care Organizations. *The Economists Voice*. 2014; 11(1):21-23. <https://doi.org/10.1515/ev-2014-0005>
66. Herzlinger R, Kumar V, Schulman K, Staman K. Innovation in health care education: a call to action. *Health Affairs Blog*. <http://healthaffairs.org/blog/2015/01/29/innovation-in-health-care-education-a-call-to-action/>.
67. Herzlinger RE, Richman BD, Schulman KA. Market-based solutions to antitrust threats--the rejection of the Partners settlement. *N Engl J Med*. 2015;372(14):1287-1289.
68. Andrews RM, Schulman KA. Enhancing the value of statewide hospital discharge data: improving clinical content and race-ethnicity data. *Health Serv Res*. 2015;50 Suppl 1:1265-1272.
69. Schulman KA, Balu S, Reed SD. Specialty pharmaceuticals for hyperlipidemia—impact on insurance premiums. *N Engl J Med*. 2015;373(17):1591-1593.
70. Wiske CP, Ogbechie OA, Schulman KA. Options to promote competitive generics markets in the United States. *JAMA*. 2015 Oct 29;1-2. doi: 10.1001/jama.2015.13498. [Epub ahead of print]
71. Haider Javed Warraich, M.D., and Kevin A. Schulman, M.D. Health Care Tax Inversions — Robbing Both Peter and Paul. *N Engl J Med* 374;11 March 17, 2016. 1005-1007
72. Schulman KA, Richman BD. Reassessing ACOs and Health Care Reform. *JAMA*. 2016 Aug 16;316(7):707-8.

73. Ticona, L, Schulman KA. Extreme Home Makeover — The Role of Intensive Home Health Care. *N Engl J Med* October, 2016.
74. Poku M, Schulman KA. We Interviewed Industry Leaders About Their Industry and They're Worried. *Harvard Business Review*. December 14, 2016.
75. Richman, Barak D. and Mitchell, Will and Vidal, Elena and Schulman, Kevin A., Pharmaceutical M&A Activity: Effects on Prices, Innovation, and Competition (May 30, 2017). *Loyola University Chicago Law Journal*, Vol. 48, 2017.
76. Herzlinger RA, Schulman KA. Diffusions of Global Innovations in Health Care: How to Make It Happen. *Health Management, Policy and Innovation*. Volume 2, Issue 1. <http://hmpi.org/2016/10/17/diffusion-of-global-innovations-in-health-care-how-to-make-it-happen/>. 2017.
77. Dabora MC, Turaga N, Schulman KA. Financing and Distribution of Pharmaceuticals in the United States. *JAMA*. 2017 May 15. doi: 10.1001/jama.2017.5607. [Epub ahead of print]
78. Richman BD, Kitzman N, Milstein A, Schulman KA. Battling the chargemaster: a simple remedy to balance billing for unavoidable out-of-network care. *Am J Manag Care*. 2017 Apr 1;23(4):e100-e105.
79. Richman BD, Schulman KA. What We Can Still Learn From India's Private Heart Hospitals. *NEJM Catalyst*. May 25, 2017.
80. Schulman KA, Reed SD. The economics of PCSK-9 Inhibitors. *Research Letter. Am Heart J* 2017;1–2.
81. Richman BD, Schulman KA. A Novel Look At Antitrust Analysis In Health Insurance Markets. *Competition Policy International (CPI)*. July, 2017.
82. Mark D. Schulman KA. PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability. *JAMA* 318 (8). 2017: 711-712.
83. Moodley S, Vasudevan A, Schulman KA. Strengthening the Private Health Sector in Africa: the PharmAccess Solution. *Health Management, Policy, and Innovation*, 2017. Volume 2, Issue 2. www.HMPI.Org.

MONOGRAPHS:

1. Brown M, Glick HA, Harrell F, et al. Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology economics workbook. *J Natl Cancer Inst Monogr*. 1998;(24):1-28.
2. Schulman KA (Chair). Barriers and Opportunities to Facilitate CER Innovation Pace & Progress, IOM Clinical Effectiveness Research Innovation Collaborative, 2009; http://www.iom.edu/~media/CER-IC%20FieldAdvancement_web.ashx
3. Kramer JM, Schulman KA. Transforming the economics of clinical trials. Institute of Medicine Forum on Drug Discovery, Development, and Translation; 2012. <http://www.iom.edu/~media/Files/Perspectives-Files/2012/Discussion-Papers/HSP-Drugs-Transforming-the-Economics.pdf>

BOOK CHAPTERS:

1. Schulman KA. The use of evaluation in pharmaceutical reimbursement decisions in the United States. In: Schubert F, editor. *Proceedings: The Canadian Collaborative Workshop on Pharmacoeconomics*. Princeton, NJ: Excerpta Medica; 1993: 19-23.
2. Eisenberg JM, Schulman KA, Glick H, Koffler H. Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Strom B, editor. *Pharmacoeconomics*. New York: John Wiley & Sons; 1994: 462-493.
3. Schulman KA. Pharmacoeconomics and clinical practice: a physician's view. In: Bootman JL, Townsend RJ, McGhan WF, editors. *Principles of Pharmacoeconomics*. Cincinnati, Ohio: Harvey Whitney Books; 1996: 252-270.
4. Schulman KA, Glick HA, Detsky AS. Introduction to decision analysis. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, editors. *Evidence Based Cardiology*. London: BMJ Books; 1998: 92-111.
5. Schulman KA, Boyko WL. Evaluating cancer costs in NCI trials. In: Bennett CL, Pajean TS, editors. *Cancer Policy: Research and Methods*. Boston: Kluwer Academic Publishers; 1998.
6. Schulman KA. Costs and outcomes. In: Stein JH, Eisenberg JM, editors. *Internal Medicine*. St. Louis: Mosby; 1998.
7. Gonzales J, Schulman K. Pharmacoeconomics. In: Richards SS, Musser WS, Gershon S, editors. *Maintenance Pharmacotherapies for Neuropsychiatric Disorders*. Philadelphia, Penn: Brunner/Mazel; 1999: 29-54.
8. Schulman KA, Glick H, Polsky D, Eisenberg JM. Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Strom BL, editor. *Pharmacoeconomics*. 2nd ed. Chichester, UK: John Wiley & Sons; 2000: 573-601.
9. Schulman KA, Glick HA, Polsky D, John KR, Eisenberg JM. Pharmacoeconomics. In: van Boxtel CJ, Santoso B, Edwards IR, editors. *Drug Benefits and Risks: International Textbook on Clinical Pharmacology*. Chichester, UK: John Wiley & Sons; 2001: 37-53.

10. Glick HA, Polsky DP, Schulman KA. Trial-based economic evaluations: an overview of design and analysis. In: Drummond M, McGuire A, editors. *Economic Evaluation in Health Care: Merging Theory With Practice*. Oxford, UK: Oxford University Press; 2001: 113-140.
11. Schulman KA, Seils DM. Clinical economics. In: Max MB, Lynn J, eds. *Interactive Textbook on Clinical Symptom Research* [online book]. Bethesda, Md: National Institute of Dental and Craniofacial Research; 2002. Available at <http://www.symptomresearch.org/>.
12. Schulman KA, Glick HA, Detsky AS. Introduction to decision analysis. In: Yusuf S et al, editors. *Evidence Based Cardiology*. 2nd ed. London: BMJ Books; 2003: 56-70.
13. Kaul P, Schulman KA. Costs of care and cost-effectiveness analysis: primary prevention of coronary artery disease. In: Weintraub WS, editor. *Cardiovascular Health Care Economics*. Totowa, NJ: The Humana Press, Inc; 2003: 157-172.
14. Schulman KA, Glick HA, Polsky D. Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Strom BL, editor. *Pharmacoeconomics*. 4th ed. Sussex, UK: John Wiley & Sons; 2005: 629-652.
15. Schulman KA. Pharmacoeconomics and clinical practice: a physician's view. In: Bootman JL, Townsend RJ, McGhan WF, editors. *Principles of Pharmacoeconomics*. 3rd ed. Cincinnati, Ohio: Harvey Whitney Books; 2005: 337-362.
16. Schulman KA, Glick HA, Polsky D. Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Strom BL, editor. *Textbook of Pharmacoeconomics*. Chichester, West Sussex, UK; Hoboken, NJ: John Wiley & Sons; 2007: 333-343.
17. Schulman KA. Understanding types of innovation and implications for policy. In: *Diffusion and Use of Genomic Innovations in Health and Medicine: Workshop Summary*. Washington, DC: National Academies Press; 2008.
18. Whellan DJ, Yager JEE, Friedman JY, Schulman KA. Economics and quality of life in the advanced heart failure patient. In: O'Connor CM, Stough WG, Gheorghiade M, Adams KF Jr, editors. *Managing Acute Decompensated Heart Failure*. Oxon, UK: Taylor & Francis; 2005.
19. Hall MA, Schulman KA. Property, privacy and the pursuit of integrated medical records. In: Elhauge E, editor. *The Fragmentation of U.S. Health Care: Causes and Solutions*. New York, NY: Oxford University Press; 2010.
20. Schulman KA, Glick HA, Polsky D, Reed SD. Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Strom BL, Kimmel SE, Hennessy S, editors. *Pharmacoeconomics*. 5th ed. West Sussex, UK: John Wiley & Sons; 2012: 678-708.
21. Wong YW, Schulman KA. Ethics of clinical research: an overview and emerging issues. In: Lopes RD, Harrington RA, editors. *Understanding Clinical Research*. New York, NY: McGraw-Hill Education; 2013.
22. Schulman KA. The Economics of Precision Medicine. In: *Insights and Innovation in Neuromuscular Medicine*. Rochester: AANEM, 2016.

BOOK REVIEWS, LETTERS, AND OTHER:

1. Merkel PA, Schulman KA. Ranitidine to prevent recurrence of duodenal ulcer [letter]. *N Engl J Med*. 1989;321:835-836.
2. Schulman K. Screening for colorectal cancer [letter]. *Ann Intern Med*. 1990;113:333-334.
3. Schulman KA. Book Review. The health care cost containment crisis: fears, opinions, and facts [book review]. *N Engl J Med*. 1990;322:139.
4. Hennessy S, Fogarty PM, Schulman KA, Mignott H. Gastric obstruction with extended-release tablets [letter]. *DICP*. 1991;25:678-679.
5. Schulman KA. Integrating pharmacoeconomic evaluations into phase III clinical trials: the multidisciplinary team. Proceedings of the 1992 Project Management Institute Annual Meeting: Managing Our Future. Drexel Hill: Project Management Institute; 1992: 191-195.
6. Schulman KA. Book Review. Health insurance and public policy [book review]. *Governance*. 1994;7:107-108.
7. Colson RS, Rubenstein LE, Hadley J, Schulman K. Evaluation of Payment for Trauma Physicians: Report to the Physician Payment Review Commission. Washington, DC: Georgetown University Medical Center; 1994.
8. Schulman K. Cost-effective analyses [letter]. *N Engl J Med*. 1995;332:124.
9. Schulman KA. The Politics of Health Care Reform: Lessons From the Past, Prospects for the Future [book review]. *N Engl J Med*. 1995;332:195.
10. Schulman KA. Coronary angioplasty had a lower 5-year cost than bypass surgery only in patients with 2-vessel coronary disease. *ACP J Club*. 1997;127:25.
11. Drummond M, Schulman K, Weinstein M, Jonsson B. From efficacy to cost-effectiveness. *OHE Briefing*. 1998;37:1-12.
12. Schulman KA, Berlin JA, Escarce JJ. Race, sex, and physicians' referrals for cardiac catheterization [letter]. *N Engl J Med*. 1999;341:285-287.

13. Weinfurt KP, Rathore SS, Schulman KA. ACI-TIPI clinical trial: acute cardiac ischemia time-insensitive predictive instrument [letter]. *Ann Intern Med.* 1999;131:476-477.
14. Cai L, Weinfurt KP. An SAS/IML module for Johnson-Neyman procedure. *Appl Psych Meas.* 1999;23:308.
15. Berger AK, Schulman KA, Gersh BJ. Primary angioplasty vs thrombolysis in the elderly [letter]. *JAMA.* 2000;283:601.
16. Sulmasy DP, Freeman VG, Schulman KA. The factuality of health records [letter]. *Arch Intern Med.* 2000;160:2224-2225.
17. Gonzales J, Kaufman J, Schulman K. Pharmacy Benefits Managers' Drug Formulary Recommendations: Implications for Older Americans. 2000-20. Washington, DC: Association of American Retired Persons; 2000.
18. Schulman KA, Seils DM, Califf RM. Clinical-trial agreements between medical schools and industry [letter]. *N Engl J Med.* 2003;348:476-478.
19. Meropol NJ, Weinfurt KP, Schulman KA. In reply—Phase I trials: physician and patient perceptions [letter]. *J Clin Oncol.* 2003;21:4659-4660.
20. Meropol NJ, Castel LD, Schulman KA, Weinfurt KP. In reply—Physician-patient communication in phase I cancer trials [letter]. *J Clin Oncol.* 2004;22:572-573.
21. Reed SD, Radeva JI, Schulman KA. Re: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer [letter]. *J Urol.* 2004;172(5 Part 1):2082.
22. Schulman KA. To cut health costs, try going to the mall. *News and Observer* (Raleigh, NC). June 24, 2005: A17.
23. Schulman KA. Medicare and cost-effectiveness analysis [letter]. *N Engl J Med.* 2006;354:207.
24. Schulman KA. Free to buy vaccines, for everyone's good. *News and Observer* (Raleigh, NC). August 29, 2006: A9.
25. Schulman KA. Let's bring drug and medical device safety into the 21st century. *Baltimore Sun.* February 19, 2007: A9.
26. Glickman SW, Rasiel EB, Hamilton CD, Schulman KA. Developing drugs for tuberculosis [letter]. *Science.* 2007;315:1076-1077.
27. Schulman KA. Kid tested, government approved? *Pharmaceutical Executive.* 2007;27(5):78-86.
28. Schulman KA. Prescribing by Numbers: Drugs and the Definition of Disease [book review]. *N Engl J Med.* 2007;357:516.
29. Meropol NJ, Schulman KA. In reply--Health economics in the *Journal of Clinical Oncology* and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab [letter]. *J Clin Oncol.* 2007;25:3383.
30. Glickman SW, Schulman KA, Cairns CB. Primary PCI in ST-segment elevation myocardial infarction [letter]. *N Engl J Med.* 2008;358:1751-1752.
31. Richman BD, Mitchell W, Schulman KA. Searching for industry modernization. *Modern Physician.* February 9, 2009. Available at: www.modernhealthcare.com/article/20090209/MODERNPHYSICIAN/302019971.
32. Glickman SW, Cairns CB, Schulman KA. Ethical and scientific implications of the globalization of clinical research. *N Engl J Med.* 2009;360(26):2793.
33. Massie BM, Ammon SE, Collins JF, et al. Response to letter regarding article, 'Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial'. *Circulation.* 2009;120:e165.
34. Schulman KA. Petryna, Adriana. 2009. When experiments travel: Clinical trials and the global search for human subjects. Princeton University Press, ISBN 978-0-691-12657-9. 270 pp. *J Bioeth Inq.* 2011;8(1):95-96.
35. Richman BD, Schulman KA. Privatizing Medicare won't slow rising costs. *Des Moines Register.* December 22, 2011.
36. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of adverse events with therapies for age-related macular degeneration: a response--reply. *Arch Ophthalmol.* 2012;130(1):125-126.
37. Curtis LH, Hammill BG, Schulman KA, Cousins SW. System and ocular risks associated with therapies for macular degeneration: clarification vs confusion--reply. *Arch Ophthalmol.* 2012;130(6):806-807.
38. Dinan MA, Carpenter WR, Patz E Jr, et al. Reply to M.S. Hofman et al. *J Clin Oncol.* 2013;31(6):820.

CASE STUDIES

Published Case Studies:

1. Herzlinger RE, Schulman KA, Dijols F. Improving Melanoma Screening: MELA Sciences. Harvard Business School Case 315-042; December 2014.
2. Herzlinger RE, Schulman KA, Upke FF. MedCath Corporation (C). Harvard Business School Supplement 315-018; February 2015.
3. Schulman KA. Alnylam: Building a Biotechnology Powerhouse. Harvard Business School Case 316-113. 2016.
4. Schulman KA, Shaw MN. Innovation at Zimmer Spine. Harvard Business School Case. 316-106; 2016.
5. Schulman KA, Balu S. Health Catalyst. Harvard Business School Case 316-098; 2016.
6. Schulman KA. Savannah Informatics. Harvard Business School Case 316-111. 2016.
7. Schulman KA, Little L, Mullangi S, Schleicher S. AbbVie. Harvard Business School Case 316-095. 2016.

8. Schulman, KA, Gresh J. Product Portfolio Management at Genentech. Harvard Business School Case 317-012. July, 2016.
9. Schulman KA, Muhammad Pate, Carbell G. Health Systems in the Developing World. Harvard Business School Background Note 316-112. 2016.
10. Schulman KA, Rasiel E, Balu S. Blue D Pharmaceuticals. Harvard Business School Case 317-014. 2016.
11. Schulman KA, Dabora M. Nutrition Science Initiative: Are All Calories Created Equal? Harvard Business School Case. 317-033. 2017.
12. Schulman KA, Strickland M. Kada Orthopedics: A Bone of Contention. Harvard Business School Case. N9-317-091. 2017
13. Schulman, KA, Kontchou Nelly-Ange. Shisong Cardiac Center: Kumbo, Cameroon. Harvard Business School Case. 317-085. 2017.
14. Schulman KA, Moodley S, Vasudevan A. PharmAccess and the M-TIBA Platform: Leveraging Mobile Technology in the Developing World. Harvard Business School Case. 317-103; 2017.
15. Schulman KA, Xiao Yu, Hwang A. China Hospital, Inc. Harvard Business School Case. 317-104. 2017.
16. Schulman KA, Cheek C (with Bo L). From mHealth Hackathon to Reality: Diabetes Care. Harvard Business School Case. 317-105. 2017.
17. Schulman KA, Leya G, Beveridge C. Obesity Management at Kaiser Permanente: A New Mindset For Healthcare Delivery? 317-106. 2017.

In Development:

18. Schulman KA. Commercialization Strategy Consulting: Should We Invest in a Phase 2 Study in Ankylosing Spondylitis? Harvard Business School Case N-316-097. 2014.*
*Awaiting Company Authorization

COMPUTER PROGRAMS:

1. Schulman KA, Drummond M, Bootman JL, Rice D, Torrance G, Steinberg E, Sloan F, eds. *Health Economics* [computer program]. Version 1. East Hanover, NJ: Sandoz Pharmaceuticals Corporation; 1996.

WEBCOURSES:

1. Herzlinger RE, Seltzer MI, Schulman KA. Innovating in Health Care. HarvardX. (2014) <https://www.edx.org/course/innovating-health-care-harvardx-bus5-1x#.VPi9G1PF81o>
2. Business of Healthcare Academy, Health Policy 1. 2014. <http://www.medscape.org/marketplace/bhcademy>
3. Business of Healthcare Academy, Health Policy 2. 2014. <http://www.medscape.org/marketplace/bhcademy>

PATENTS:

- | | |
|-------------------|--|
| 9,305,059 | Methods, systems, and computer readable media for dynamically selecting questions to be presented in a survey. Issued April 5, 2016. Assigned to the University of North Carolina. |
| PCT/US2017/027310 | Systems And Methods For Mobile Patient-Centric Electronic Health Record Data. Provision Filed April 15, 2016. Full Application filed April 13, 2017. Assigned to Duke University. |